ClinicalTrials.gg
Active, not recruitingNCT04162210DREAMM-3Updated Jul 1, 2026Results posted

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 3 interventional study of Belantamab mafodotin and Pom/dex (Pomalidomide plus low dose Dexamethasone) in Multiple Myeloma, sponsored by GlaxoSmithKline. Active, not recruiting at 136 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing belantamab mafodotin in Multiple Myeloma — 15 open to participants now, 35 under way, 8 of them phase 3. belantamab mafodotin · Multiple Myeloma.

Enrollment
4th of 49
325 · median 50
Started
2020
with 5 others
Phase 3
9 of 49
2 open now
Primary completion
2022-09
later than 0 of 34 live
Registered
6th of 49
by date
Lead sponsor
24 of 49
GlaxoSmithKline

Among the 49 studies testing belantamab mafodotin in Multiple Myeloma, this one is the 4th largest by enrollment, is one of 6 that started in 2020, is one of 9 in phase 3, reaches primary completion later than 0 of the 34 other live ones, and was the 6th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 49 studies testing belantamab mafodotin in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About belantamab mafodotin

belantamab mafodotin: first FDA approval 2020 (Blenrep), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies testing belantamab mafodotin in Multiple Myeloma, or all of them as a file.
02

Study summary

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Belantamab mafodotin
  • Pomalidomide
  • Dexamethasone
  • Relapsed/Refractory Multiple Myeloma
  • Driving Excellence in Approaches to Multiple Myeloma 3 (DREAMM 3)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed .
  • Participants must be 18 or older, at the time of signing the informed consent. In Republic of Korea, participants must be over 19 years of age inclusive, at the time of signing informed consent.
  • (ECOG) performance status of 0 to 2.
  • or cytologically confirmed diagnosis of Multiple myeloma (MM) as defined according to IMWG, and : Has undergone stem cell transplant (SCT), or is considered transplant ineligible; Has received at least 2 prior lines of anti-myeloma treatments, including at least 2 consecutive cycles of both lenalidomide and a proteasome inhibitor (given separately or in combination), and must have documented disease progression on, or within 60 days of, completion of the last treatment or must be non-responsive while on last treatment, where non-responsive is defined as not achieving at least Minimal Response (MR) after 2 complete treatment cycles. In such cases lack of achieving of at least MR must be determined no earlier than at least 4 weeks after the last treatment.
  • Has with at least one of the following: Serum M-protein >=0.5 gram per deciliter (g/dL) (>=5 gram per Liter); Urine M-protein >=200 mg/24 hours; Serum free light chain (FLC) assay: Involved FLC level >=10 milligram per deciliter (mg/dL) (>=100 mg/L) and an abnormal serum FLC ratio (\<0.26 or >1.65).
  • Participants with a history of autologous SCT are eligible for study participation provided the following eligibility criteria are met: Transplant was >100 days prior to initiating study treatment; No active infection(s).
  • Adequate organ system functions as defined: (ANC) >=1.0*10\^9/L; >= 8.0 g/dL; >= 50x10\^9/L; Total \<=1.5* (ULN) (isolated bilirubin >1.5*ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent); \<=2.5*ULN; Estimated (eGFR) >=30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2); Spot urine (albumin/creatinine ratios) \<=500 milligram per gram (mg/g) (56 milligram per millimoles [mg/mmol]).
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during the intervention period and until 6 months after the last dose of study intervention to allow for clearance of any altered sperm: Refrain from donating sperm PLUS, either: Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR Must agree to use contraception/barrier as detailed below depending on whether they are randomised to Arm 1 (belantamab mafodotin) or Arm 2 (pom/dex), even if they have undergone a successful vasectomy: Agree to use a male condom throughout study treatment including the 6 month follow-up period even if they have undergone a successful vasectomy and a female partner to use an additional highly effective contraceptive method with a failure rate of \<1 percent per year when having sexual intercourse with a pregnant woman or a woman of who is not currently pregnant. Four weeks for male participants on Treatment Arm 2 (pom/dex).
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and agrees to abide by the following: Arm 1 (belantamab mafodotin): Use a contraceptive method that is highly effective (with a failure rate of \<1 percent per year) which includes abstinence, preferably with low user dependency during the intervention period and for 4 months after the last dose of study treatment. Arm 2 (pom/dex): Due to pomalidomide being a thalidomide analogue with risk for embryofetal toxicity and prescribed under a pregnancy prevention/controlled distribution program, WOCBP participants will be eligible if they commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control (one method that is highly effective), beginning 4 weeks prior to initiating treatment with pomalidomide, during therapy, during dose interruptions and continuing for at least 4 weeks following discontinuation of pomalidomide treatment. Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing pomalidomide therapy. And agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should confirm the effectiveness of the contraceptive method(s) ahead of the first dose of study intervention.
  • All prior treatment-related toxicities (defined by National Cancer Institute- Common Toxicity Criteria for Adverse Events [], version 5.0, 2017) must be \<=Grade 1 at the time of enrollment, except for alopecia and Grade 2 peripheral neuropathy.

Exclusion criteria

Exclusion Criteria:

  • Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes); active plasma cell leukemia at the time of screening.
  • Systemic anti-myeloma therapy or use of an drug within \<14 days or 5 half-lives, whichever is shorter, before the first dose of study intervention.
  • Prior treatment with an anti-MM monoclonal antibody within 30 days prior to receiving the first dose of study intervention.
  • Prior B cell maturation antigen (BCMA)-targeted therapy or prior pomalidomide treatment.
  • Plasmapheresis within 7 days prior to the first dose of study intervention.
  • Prior stem cell transplant. (Participants who have undergone syngeneic transplant will be allowed only if no history of, or currently active, [GvHD]).
  • Any major surgery within the last 4 weeks.
  • Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfil criteria as described in inclusion criteria.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining , or compliance with study procedures.
  • History of (non-infectious) pneumonitis that required , or current pneumonitis.
  • Evidence of active mucosal or internal bleeding.
  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis. (Stable chronic liver disease [including Gilbert's syndrome or asymptomatic gallstones] or hepatobiliary involvement of is acceptable if participant otherwise meets entry criteria)
  • Participants with previous or concurrent malignancies other than multiple myeloma are excluded, unless the second malignancy has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease. (Participants with curatively treated non-melanoma skin cancer are allowed without a 2-year restriction).
  • Evidence of cardiovascular risk including any of the following: Evidence of current uncontrolled arrhythmias including clinically significant (ECG) abnormalities including 2nd degree (Mobitz Type II) or 3rd degree atrioventricular block; History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening; Class III or IV heart failure as defined by the (NYHA) functional classification system; Uncontrolled hypertension.
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin, pomalidomide, dexamethasone or any of the components of the study intervention.
  • Pregnant or lactating female.
  • Active infection requiring treatment.
  • Known (HIV), unless the participant can meet all of the following criteria: Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load \<400 copies/mL; CD4+ T-cell (CD4+) counts ≥350 cells/uL; No history of AIDS-defining opportunistic infections within the last 12 months.(Consideration must be given to ART and prophylactic antimicrobials that may have a drug-drug interaction and/or overlapping toxicities with belantamab mafodotin or other combination products as relevant)
  • Participants with will be excluded unless the following criteria can be met: If the participant is hepatitis B core antibody (HbcAb) positive or hepatitis B surface antigen (HbsAg) negative, then hepatitis B virus (HBV) deoxyribonucleic acid (DNA) should be undectectable at the time of screening; If HbsAg+ at screening or \<=3 months prior to first dose of study treatment, then HBV DNA should be undetectable, highly effective antiviral treatment should be started ≥4 weeks prior to first dose of study treatment, exclusion of participants with cirrhosis and participants in Japan must test hepatitis B e antigen (HBeAg) and hepatitis B e antibody (HBeAb ).
  • Positive antibody test result or positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment unless the participant can meet the following criteria: Hepatitis C RNA test negative at Screening and successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative HCV RNA test after a of at least 4 weeks (Hepatitis RNA is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing).
  • Participants unable to tolerate thromboembolic prophylaxis.
  • Current corneal epithelial disease except for mild punctate keratopathy.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    Participants receiving Belantamab mafodotin

    Participants will receive belantamab mafodotin single agent dose on Day 1 of Q3W

    Drug: Belantamab mafodotin

  • Active comparator
    Participants receiving pom/dex

    Participants will receive pomalidomide daily on Days 1 to 21 of each 28-day cycle, with dexamethasone once weekly on Days 1, 8, 15 and 22.

    Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)

Interventions

  • Belantamab mafodotin will be administered.

  • DrugPom/dex (Pomalidomide plus low dose Dexamethasone)

    Pomalidomide and Dexamethasone will be administered.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)

    PFS is time from randomization until earliest date of progressive disease (PD), or death due to any cause per investigator-assessed response per IMWG. PD is ≥25% increase from nadir in any of following: serum M-protein (absolute increase ≥0.5 gram per deciliter \[g/dL\]),urine M-protein(absolute increase ≥200 mg/24hr),difference between involved/uninvolved FLC levels (absolute increase \>10 mg/dL) in patients without measurable serum and urine M-protein levels, or bone marrow plasma-cell percentage irrespective of baseline status (absolute increase ≥10%) in patients without measurable serum and urine M-protein levels and without measurable involved FLC levels; appearance of new lesion,≥50% increase in longest diameter of a lesion previously measured \>1cm in short axis, or ≥50% increase from nadir in sum of products of two longest perpendicular diameters of more than 1 lesion; ≥50% increase in circulating plasma cells (minimum of 200 cells/microliter) if this is only measure of disease.

    Time frame: Up to 27 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization until death due to any cause.

    Time frame: Up to approximately 263 weeks

  2. Overall Response Rate (ORR)

    Overall Response Rate is defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. PR: ≥50% reduction of serum M-protein and reduction in 24-hour (h) urinary M-protein by ≥90% or to \<200 mg/24-h; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24-h; CR:negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR:stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

    Time frame: Up to approximately 263 weeks

  3. Clinical Benefit Rate (CBR)

    Clinical benefit rate is defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.

    Time frame: Up to approximately 263 weeks

  4. Duration of Response (DoR)

    Duration of response is defined as the time from first documented evidence of PR or better, to the time when disease progression (PD) is documented per IMWG response criteria; or death due to PD occurs among participants who achieve an overall response, i.e. confirmed PR or better. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h). PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \<200 mg/24 h.

    Time frame: Up to approximately 263 weeks

  5. Time to Response (TTR)

    TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve confirmed PR or better. PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90%/\<200mg/24 h.

    Time frame: Up to approximately 263 weeks

  6. Time to Progression (TTP)

    TTP is defined as the time from the date of randomization until the earliest date of documented PD (per IMWG Response Criteria) or death due to PD. PD: increase of \>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>=0.5 g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% increase from nadir in Sum of the Products of the maximal perpendicular Diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in the longest diameter of previous lesion \>1 cm in short axis.

    Time frame: Up to approximately 263 weeks

  7. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. TEAE is an event that emerged during treatment having been absent pre-treatment or worsened relative to the pre-treatment state. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 263 weeks

  8. Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-baseline Relative to Baseline

    Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Basophils (Baso), Mean Corpuscular Hemoglobin Concentration (MCHC), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Volume (MCV), Erythrocytes (Ery), Hematocrit (Hct), Monocytes (Mono), Reticulocytes (Ret), Leukocytes (Leu), Eosinophils (Eosi), Lymphocytes (Lym), Neutrophils (Neu)\]

    Time frame: Baseline (Day 1) and up to approximately 263 weeks

  9. Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Hematology

    Blood samples were collected for evaluation of hematology parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[White Blood Cells (WBC)\]

    Time frame: Baseline (Day 1) and up to approximately 263 weeks

  10. Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-baseline Relative to Baseline

    Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Kappa Light (K Lt), Lambda (λ),Monoclonal (Mc), Protein (P), Change (Cge), Alpha (α), Beta (β), Creatine Kinase (CK), Gamma (γ) ,Immunoglobulin (I-Globulin), Indirect (In.)\]

    Time frame: Baseline (Day 1) and up to approximately 263 weeks

  11. Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Clinical Chemistry

    Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate Aminotransferase (AST), Creatine Kinase (CPK), Gamma Glutamyl Transferase (GGT)\]

    Time frame: Baseline (Day 1) and Up to approximately 263 weeks

  12. Number of Participants With Shift in Urine Albumin Creatinine Ratio From Baseline to Worst Post-Baseline

    Urine samples were analyzed for spot urine albumin/creatinine ratio (UACR)\[milligrams/grams (mg/g)\]. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The "worst post-baseline value" is defined as the highest UACR measurement recorded for a participant after the baseline assessment and up to the end of the study observation period. The "shift" will be calculated as the difference between this worst post-baseline UACR value and the baseline UACR value (Worst Post-Baseline UACR - Baseline UACR). Each category is reported as "Baseline category, Worst post-baseline category." Ranges are inclusive and expressed as \[lower-upper\].

    Time frame: Baseline (Day 1) and Up to approximately 263 weeks

  13. Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores

    BCVA score was assessed individually for each eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change from baseline categories are presented for right and left eyes. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from baseline \<0.12 logMAR score; a possible worsened vision was defined as a change from baseline \>=0.12 to \<0.3 logMAR score; a definite worsened vision was defined as a change from baseline \>=0.3 logMAR score. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1) and up to approximately 263 weeks

  14. Observed Plasma Concentrations of Belantamab Mafodotin- Antibody-drug Conjugate (ADC)

    Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

    Time frame: Pre-dose on Day (D)1 of Cycles(C)1,2,3,4,6,9,12,18,24,30,36,42; End of Infusion (EOI) on D1 of C1,2,3,4&6; Start of infusion (SOI) + 2 hours(h) on D1,SOI + 24 h on D1; D4,D8-15,D22 of C1&C3; D1 of C2,3,4&6; C3D2; & End of Treatment(EOT) (~242 weeks)

  15. Observed Plasma Concentrations of Belantamab Mafodotin- Total Monoclonal Antibody (mAb)

    Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

    Time frame: Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; SOI + 24h on D1&2 of C1&3; D4, D8-15, D22 of C1&3; D1of C2,3,4 & 6; D2 of C3; and EOT (~242 weeks)

  16. Observed Plasma Concentrations of Belantamab Mafodotin-Cys-mc Microtubular Inhibitor Monomethyl Auristatin-F (MMAF)

    Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

    Time frame: Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; D1 SOI + 2 h of C1&3; D2 SOI + 24h of C1&3; D4, D8-15, D22 of C1&3; D1 of C2,3,4,6,9,12,18,24 & 30; D2 of C3; and EOT (~242 weeks)

  17. Number of Participants With Post-baseline Positive Anti-Drug Antibody (ADAs) Against Belantamab Mafodotin

    Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

    Time frame: Upto approximately 263 weeks

  18. Titers of ADAs Against Belantamab Mafodotin

    Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin . Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented.

    Time frame: Up to approximately 263 weeks

  19. Number of Participants With Symptomatic Adverse Effects as Measured by the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. It includes symptomatic toxicities drawn from the CTCAE like blurred vision, chills, constipation, decreased appetite, fatigue, general pain, mouth/throat sores, nausea, nosebleed, shortness of breath, vomiting, watery eyes, cough, itchy, loose/watery stools, Numb/Tingling Hands/Feet (N/T H/F), Pain/Burning (P/B) and Problems Tasting Food/Drink (Prob Tasting F/D) . Items are scored individually on a 0 to 4 scale for severity, frequency and interference. A score of 0 indicates no symptom or interference, while higher score of 4 signify increasing severity, frequency, and interference with daily activities.

    Time frame: Up to approximately 263 weeks

  20. Change From Baseline (CFB) in Ocular Surface Disease Index (OSDI) Total Score

    OSDI is 12-item patient-reported outcomes questionnaire designed to provide rapid assessment of range of ocular surface symptoms, including symptoms related to chronic dry eye, severity, and impact on patient's ability to function. In addition to an overall score, there are three subscales of OSDI: ocular symptoms, vision-related function, and environmental triggers. OSDI items are scored on a 0 to 4 Likert-type scale, where 0 = None of the time and 4 = All of the time. Total OSDI score = (\[sum of scores for all questions answered×100\]/\[total number of questions answered×4\]). Subscale scores are computed similarly with only questions from each subscale used to generate its own score. Any subscales analyzed separately would also have a maximum possible score of 100. A score of 100=to complete disability, while a score of 0=to no disability. Decrease in score from baseline means improvement

    Time frame: Baseline (Day 1) and Up to approximately 263 weeks

  21. Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score.

    The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], emotional functioning \[EF\] cognitive functioning \[CF\] and social functioning \[SF\]), three symptom scales (fatigue, nausea/vomiting \[N/V\] and pain), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (dyspnea, insomnia, appetite loss \[AL\], constipation, diarrhea and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238, End of Treatment (~242 weeks) and Follow up (~ 263 weeks)

  22. Change From Baseline (CFB) in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score

    The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238, End of Treatment (~242 weeks) and Follow up (~263 weeks)

  23. Change From Baseline (CFB) in EORTC IL52 Score

    European Organization for Research and Treatment of Cancer Item Library 52 (EORTC-QLQ-IL52) is disease symptoms domain from EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module) (EORTC QLQ-MY20). Disease symptoms domain of IL52 contain 6 items covering following concepts: bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. IL52 items are scored on 1 to 4 Likert-type scale, where 1 = Not at all, 2 = A little, 3 = Quite a bit, and 4 = Very much. A raw score is then calculated as mean of completed item responses across 6 disease symptom items. For symptom scales, this raw score is linearly transformed to a 0 to 100 scale using the formula: \[(raw score - 1) / 3\] × 100. Under this approach, a score of 0 indicates no symptoms across items, while a score of 100 indicates the highest level of symptom burden. Accordingly, higher scores indicate greater symptom burden or worse disease symptoms

    Time frame: Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238

  24. Number of Participants With Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate is defined as the percentage of participants who are MRD negative by Next generation sequencing (NGS) method. The number of participants with MRD negativity has been presented

    Time frame: Up to approximately 263 weeks

07

Results

Posted Oct 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneBelantamab MafodotinPomalidomide Plus Dexamethasone
Started218107
Safety population217102
Completed12668
Not completed9239
Withdrew: Lost to follow-up41
Withdrew: Physician decision5126
Withdrew: Withdrawal by subject229
Withdrew: Ongoing at the time of analysis153

Outcome measures

SecondaryOverall Survival (OS)

OS is defined as the time from randomization until death due to any cause.

Time frame:
Up to approximately 263 weeks
Reported as:
Median · Months
Overall Survival (OS)
MonthsBelantamab MafodotinPomalidomide Plus Dexamethasone
Overall Survival (OS)24.0 (19.4 to 33.2)22.9 (16.0 to 29.3)
Statistical analysis
  • Belantamab Mafodotin vs Pomalidomide Plus Dexamethasone · Log Rank · p = 0.440 · Hazard ratio (hr): 0.98 · 95% CI 0.73 to 1.30One-sided p-value from stratified log-rank test were adjusted for previous treatment with anti-CD38, ISS staging and number of prior lines of therapy.
SecondaryOverall Response Rate (ORR)

Overall Response Rate is defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, very good partial response \[VGPR\], complete response \[CR\] and stringent complete response \[sCR\]), according to the International Myeloma Working Group (IMWG) Response Criteria. PR: ≥50% reduction of serum M-protein and reduction in 24-hour (h) urinary M-protein by ≥90% or to \<200 mg/24-h; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component \<100 mg/24-h; CR:negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND \<5% plasmacytomas in the bone marrow; sCR:stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.

Time frame:
Up to approximately 263 weeks
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Overall Response Rate (ORR)41 (34.7 to 48.1)36 (26.5 to 45.4)
SecondaryClinical Benefit Rate (CBR)

Clinical benefit rate is defined as the percentage of participants with a confirmed minimal response (MR) or better according to the IMWG Response Criteria. MR is \>= 25% but \< 49% reduction of serum M-protein and reduction in 24-hour urinary M-protein by 50-89%.

Time frame:
Up to approximately 263 weeks
Reported as:
Number · Percentage of Participants
Clinical Benefit Rate (CBR)
Percentage of ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Clinical Benefit Rate (CBR)47 (40.5 to 54.1)47 (37.0 to 56.6)
SecondaryDuration of Response (DoR)

Duration of response is defined as the time from first documented evidence of PR or better, to the time when disease progression (PD) is documented per IMWG response criteria; or death due to PD occurs among participants who achieve an overall response, i.e. confirmed PR or better. PD= Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>= 0.5 g/dL; Serum M-protein increase \>= 1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>= 200 mg per 24 h). PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \<200 mg/24 h.

Time frame:
Up to approximately 263 weeks
Reported as:
Median · Months
Duration of Response (DoR)
MonthsBelantamab MafodotinPomalidomide Plus Dexamethasone
Duration of Response (DoR)25.3 (20.7 to 31.8)9.9 (7.6 to 20.2)
SecondaryTime to Response (TTR)

TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better) among participants who achieve confirmed PR or better. PR: \>=50% reduction of serum M-protein \& reduction in 24h urinary M-protein by \>=90%/\<200mg/24 h.

Time frame:
Up to approximately 263 weeks
Reported as:
Median · Months
Time to Response (TTR)
MonthsBelantamab MafodotinPomalidomide Plus Dexamethasone
Time to Response (TTR)2.10 (0.89 to 3.52)1.53 (0.89 to 2.33)
SecondaryTime to Progression (TTP)

TTP is defined as the time from the date of randomization until the earliest date of documented PD (per IMWG Response Criteria) or death due to PD. PD: increase of \>=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be \>=0.5 g/dL), serum M-protein increase \>=1g/dL if lowest M component was \>=5g/dL; urine M-component (absolute increase must be \>=200mg/24 hour),appearance of new lesion(s), \>=50% increase from nadir in Sum of the Products of the maximal perpendicular Diameters of measured lesions (SPD) of \>1 lesion, or \>=50% increase in the longest diameter of previous lesion \>1 cm in short axis.

Time frame:
Up to approximately 263 weeks
Reported as:
Median · Months
Time to Progression (TTP)
MonthsBelantamab MafodotinPomalidomide Plus Dexamethasone
Time to Progression (TTP)11.3 (7.0 to 14.6)8.6 (5.7 to 11.8)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. TEAE is an event that emerged during treatment having been absent pre-treatment or worsened relative to the pre-treatment state. AEs were to be coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Number of Participants With Treatment Emergent Adverse Events (TEAEs)21298
SecondaryNumber of Participants With Worst Case Hematology Results Relative to Normal Range Post-baseline Relative to Baseline

Blood samples were collected for evaluation of hematology parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Basophils (Baso), Mean Corpuscular Hemoglobin Concentration (MCHC), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Volume (MCV), Erythrocytes (Ery), Hematocrit (Hct), Monocytes (Mono), Reticulocytes (Ret), Leukocytes (Leu), Eosinophils (Eosi), Lymphocytes (Lym), Neutrophils (Neu)\]

Time frame:
Baseline (Day 1) and up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-baseline Relative to Baseline
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Baso, Decrease to Low84
Baso, Change to Normal or No Change14747
Baso, Increase to High1419
MCHC, Decrease to Low6930
MCHC, Change to Normal or No Change12959
MCHC, Increase to High199
MCH, Decrease to Low5613
MCH, Change to Normal or No Change14268
MCH, Increase to High2324
MCV, Decrease to Low4410
MCV, Change to Normal or No Change15165
MCV, Increase to High2525
Ery, Decrease to Low1810
Ery, Change to Normal or No Change16579
Ery, Increase to High275
Hct, Decrease to Low2319
Hct, Change to Normal or No Change18278
Hct, Increase to High132
Mono, Decrease to Low2025
Mono, Change to Normal or No Change10320
Mono, Increase to High5139
Ret, Decrease to Low2314
Ret, Change to Normal or No Change5522
Ret, Increase to High4113
Baso/Leu, Decrease to Low00
Baso/Leu, Change to Normal or No Change3610
Baso/Leu, Increase to High212
Eosi/Leu, Decrease to Low113
Eosi/Leu, Change to Normal or No Change237
Eosi/Leu, Increase to High713
Lym/Leu, Decrease to Low148
Lym/Leu, Change to Normal or No Change184
Lym/Leu, Increase to High711
Mono/Leu, Decrease to Low84
Mono/Leu, Change to Normal or No Change219
Mono/Leu, Increase to High1310
Neu/Leu, Decrease to Low811
Neu/Leu, Change to Normal or No Change174
Neu/Leu, Increase to High119
SecondaryNumber of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Hematology

Blood samples were collected for evaluation of hematology parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE version 5.0. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[White Blood Cells (WBC)\]

Time frame:
Baseline (Day 1) and up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Hematology
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Anemia, Increase (Inc) G1-G48757
Anemia, Inc G2-G47339
Anemia, Inc G3-G43921
Hemoglobin increased, Inc G1-G460
Hemoglobin increased, Inc G2-G410
Hemoglobin increased, Inc G3-G410
Lymphocyte count decreased, Inc G1-G410571
Lymphocyte count decreased, Inc G2-G47755
Lymphocyte count decreased, Inc G3-G44327
Lymphocyte count increased, Inc G1-G484
Lymphocyte count increased, Inc G2-G484
Lymphocyte count increased, Inc G3-G400
Neutrophil count decreased, Inc G1-G49683
Neutrophil count decreased, Inc G2-G47176
Neutrophil count decreased, Inc G3-G43258
Platelet count decreased, Inc G1-G414562
Platelet count decreased, Inc G2-G49838
Platelet count decreased, Inc G3-G46721
Eosi, Inc G1-G43334
WBC decreased, Inc G1-G49183
WBC decreased, Inc G2-G46169
WBC decreased, Inc G3-G42434
SecondaryNumber of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-baseline Relative to Baseline

Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of worst-case change from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by CTCAE v5.0. The number of participants with decreases to low from baseline, changes to normal or no changes from baseline, and increases to high values have been presented. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Kappa Light (K Lt), Lambda (λ),Monoclonal (Mc), Protein (P), Change (Cge), Alpha (α), Beta (β), Creatine Kinase (CK), Gamma (γ) ,Immunoglobulin (I-Globulin), Indirect (In.)\]

Time frame:
Baseline (Day 1) and up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range Post-baseline Relative to Baseline
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Calcium, Decrease to Low4240
Calcium, Change to Normal (N) or No Change13849
Calcium, Increase to High3910
Carbon Dioxide, Decrease to Low6128
Carbon Dioxide, Change to N or No Change9344
Carbon Dioxide, Increase to High3112
Chloride, Decrease to Low3012
Chloride, Change to N or No Change13256
Chloride, Increase to High5431
Protein, Decrease to Low6342
Protein, Change to N or No Change13551
Protein, Increase to High196
K Lt C (Chain), Decrease to Low307
K Lt C, Change to N or No Change16978
K Lt C, Increase to High913
K Lt C,Free, Decrease to Low33
K Lt C, Free, Change to N or No Change184
K Lt C, Free, Increase to High94
K Lt C,Free/λ Lt C, Decrease to Low41
K Lt C,Free/λ Lt C, Change to N or No Change105
K Lt C,Free/λ Lt C, Increase to High135
λ Lt C, Decrease to Low462
λ Lt C, Change to N or No Change15983
λ Lt C, Increase to High513
λ Lt C, Free, Decrease to Low123
λ Lt C, Free, Change to N or No Change127
λ Lt C, Free, Increase to High51
Mc Protein, Change to N or No Change116
Mc Protein, Increase to High183
Mc Protein Spike, Change to N or No Change19388
Mc Protein Spike, Increase to High71
Mc P Spike/Total P, Cge to N or No Cge19388
Mc P Spike/Total P, Increase to High71
No. of Mc P Spikes, Cge to N or No Cge19388
No. of Mc P Spikes, Increase to High71
α -1 Globulin/Total P, Decrease to Low61
α -1 Globulin/Total P,Cge to N or No Cge10341
α -1 Globulin/Total P, Increase to High10457
α -2 Globulin/Total P, Decrease to Low143
α -2 Globulin/Total P, Cge to N or No Cge12747
α -2 Globulin/Total P, Increase to High7249
β -2 microglobulin, Cge to N or No Cge4118
β -2 microglobulin, Increase to High11
CK , Increase to High01
Direct Bilirubin, Decrease to Low21
Direct Bilirubin, Cge to N or No Cge14360
Direct Bilirubin, Increase to High4630
γ Globulin/Total P, Decrease to Low5017
γ Globulin/Total P, Cge to N or No Cge15777
γ Globulin/Total P, Increase to High65
I-Globulin A, Decrease to Low20
I-Globulin A, Cge to N or No Cge130
I-Globulin A,, Increase to High01
I-Globulin G, Decrease to Low20
I-Globulin G, Change to Normal or No Change70
I-Globulin G, Increase to High11
I-Globulin M, Decrease to Low42
I-Globulin M, Cge to N or No Cge122
In. Bilirubin, Decrease to Low10
In. Bilirubin, Cge to N or No Cge01
In. Bilirubin, Increase to High11
Phosphate, Decrease to Low5642
Phosphate, Cge to N or No Cge12343
Phosphate, Increase to High3912
Thyrotropin, Decrease to Low62
Thyrotropin, Cge to N or No Cge4213
Thyrotropin, Increase to High187
Thyroxine, Decrease to Low106
Thyroxine, Cge to N or No Cge4212
Thyroxine, Increase to High133
Troponin I, Increase to High11
Urate, Decrease to Low4614
Urate, Cge to N or No Cge12867
Urate, Increase to High4417
Urea Nitrogen, Decrease to Low104
Urea Nitrogen, Cge to N or No Cge4019
Urea Nitrogen, Increase to High3717
SecondaryNumber of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Clinical Chemistry

Blood samples were collected for evaluation of clinical chemistry parameters. The summaries of maximum grade increase from Baseline with respect to normal range have been presented for only those laboratory tests that are gradable by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. \[Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate Aminotransferase (AST), Creatine Kinase (CPK), Gamma Glutamyl Transferase (GGT)\]

Time frame:
Baseline (Day 1) and Up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Maximum Grade Increase Post-Baseline Relative to Baseline in Clinical Chemistry
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
ALT Inc,G1-G48425
ALT Inc, G2-G4135
ALT Inc, G3-G432
ALP Inc, G1-G49317
ALP Inc, G2-G4182
ALP Inc, G3-G420
AST Inc, G1-G415315
AST Inc, G2-G4212
AST Inc, G3-G441
Blood bilirubin Inc, G1-G43718
Blood bilirubin Inc, G2-G4113
Blood bilirubin Inc, G3-G420
CPK increased, Inc to G1-G4575
CPK increased, Inc to G2-G4141
CPK increased, Inc to G3-G431
Creatinine increased, G1-G49140
Creatinine increased, G2-G44015
Creatinine increased, G3-G462
GGT increased, G1-G411323
GGT increased, G2-G4518
GGT increased, G3-G4224
Hyperkalemia, Inc to G1-G41810
Hyperkalemia, Inc to G2-G465
Hyperkalemia, Inc to G3-G422
Hypermagnesemia, Inc to G1-G4207
Hypermagnesemia, Inc to G2-G421
Hypermagnesemia, Inc to G3-G421
Hypernatremia, Inc to G1-G41910
Hypernatremia, Inc to G2-G431
Hypernatremia, Inc to G3-G421
Hypoalbuminemia, Inc to G1-G47441
Hypoalbuminemia, Inc to G2-G43314
Hypoalbuminemia, Inc to G3-G442
Hypoglycemia, Inc to G1-G4216
Hypoglycemia, Inc to G2-G431
Hypoglycemia, Inc to G3-G400
Hypomagnesemia, Inc to G1- G43926
Hypomagnesemia, Inc to G2-G483
Hypomagnesemia, Inc to G3-G430
Hypercalcemia, Inc to G1- G45817
Hypercalcemia, Inc to G2- G4125
Hypercalcemia, Inc to G3- G472
Hypocalcemia, Inc to G1- G44744
Hypocalcemia, Inc to G2- G486
Hypocalcemia, Inc to G3- G420
Chronic Kidney Disease (CKD), Inc to G1- G46026
CKD, Inc to G2- G45425
CKD, Inc to G3- G41011
Lactate dehydrogenase(LDH),Inc to G1- G413224
SecondaryNumber of Participants With Shift in Urine Albumin Creatinine Ratio From Baseline to Worst Post-Baseline

Urine samples were analyzed for spot urine albumin/creatinine ratio (UACR)\[milligrams/grams (mg/g)\]. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. The "worst post-baseline value" is defined as the highest UACR measurement recorded for a participant after the baseline assessment and up to the end of the study observation period. The "shift" will be calculated as the difference between this worst post-baseline UACR value and the baseline UACR value (Worst Post-Baseline UACR - Baseline UACR). Each category is reported as "Baseline category, Worst post-baseline category." Ranges are inclusive and expressed as \[lower-upper\].

Time frame:
Baseline (Day 1) and Up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Shift in Urine Albumin Creatinine Ratio From Baseline to Worst Post-Baseline
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Baseline [< 500, < 500]12957
Worst post-baseline [< 500, (500, 2000)]252
Worst post-baseline [< 500, > 2000]50
Worst post-baseline [< 500, Missing]2316
Worst post-baseline [(500, 2000), < 500]21
Worst post-baseline [(500, 2000), (500, 2000)]20
Worst post-baseline [(500, 2000), > 2000]10
Worst post-baseline [(500, 2000), Missing]00
Worst post-baseline [> 2000, < 500]00
Worst post-baseline [> 2000, (500, 2000)]00
Worst post-baseline [> 2000, > 2000]10
Worst post-baseline [> 2000, Missing]00
Worst post-baseline [Missing, < 500]2117
Worst post-baseline [Missing, (500, 2000)]20
Worst post-baseline [Missing, > 2000]10
Worst post-baseline [Missing, Missing]59
SecondaryNumber of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores

BCVA score was assessed individually for each eye. BCVA score was calculated based on the Logarithm of the Minimum Angle of Resolution (logMAR score). Any worst-case change from baseline categories are presented for right and left eyes. BCVA test scores were categorized as no change/improved vision, possible worsened vision and definite worsened vision. No change/improved vision was defined as a change from baseline \<0.12 logMAR score; a possible worsened vision was defined as a change from baseline \>=0.12 to \<0.3 logMAR score; a definite worsened vision was defined as a change from baseline \>=0.3 logMAR score. Baseline (Day 1) was defined as latest pre-dose assessment with non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1) and up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Maximum Worst-case Change From Baseline in Best Corrected Visual Acuity Test (BCVA) Scores
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Left Eye — >=3 line decrease785
Left Eye — >=2 but < 3 line decrease296
Left Eye — >=1 but < 2 line decrease2810
Left Eye — <1 line decrease or any increase6841
Right Eye — >=3 line decrease845
Right Eye — >=2 but < 3 line decrease264
Right Eye — >=1 but < 2 line decrease298
Right Eye — <1 line decrease or any increase6445
Worst Eye — >=3 line decrease987
Worst Eye — >=2 but < 3 line decrease257
Worst Eye — >=1 but < 2 line decrease3015
Worst Eye — <1 line decrease or any increase5033
SecondaryObserved Plasma Concentrations of Belantamab Mafodotin- Antibody-drug Conjugate (ADC)

Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

Time frame:
Pre-dose on Day (D)1 of Cycles(C)1,2,3,4,6,9,12,18,24,30,36,42; End of Infusion (EOI) on D1 of C1,2,3,4&6; Start of infusion (SOI) + 2 hours(h) on D1,SOI + 24 h on D1; D4,D8-15,D22 of C1&C3; D1 of C2,3,4&6; C3D2; & End of Treatment(EOT) (~242 weeks)
Reported as:
Mean · Micrograms per milliliter (ug/mL)
Observed Plasma Concentrations of Belantamab Mafodotin- Antibody-drug Conjugate (ADC)
Micrograms per milliliter (ug/mL)Belantamab Mafodotin
C1 D1, Pre-dose0.3692 ± 4.95969
C1 D1, EOI47.3332 ± 16.96867
C1 D1, SOI + 2 hours41.5745 ± 16.93490
C1 D2, SOI + 24 hours27.6062 ± 9.78065
C1 D414.0901 ± 6.98060
C1 D8-155.3548 ± 3.73879
C1 D221.7940 ± 1.49303
C2 D134.8667 ± 33.36770
C2 D1, Pre-dose2.4459 ± 5.19465
C2 D1, EOI50.3281 ± 19.73235
C3 D124.6770 ± 23.95059
C3 D1, Pre-dose3.2534 ± 4.96069
C3 D1, EOI48.0512 ± 21.57493
C3 D1, SOI + 2 hours42.4683 ± 18.02709
C3 D235.2500 ± 2.33345
C3 D2, SOI + 24 hours32.8751 ± 12.45517
C3 D421.5897 ± 12.95046
C3 D8-158.9996 ± 4.50886
C3 D223.2830 ± 1.95202
C4 D136.3300 ± 44.22246
C4 D1, Pre-dose3.7620 ± 5.53119
C4 D1, EOI49.9998 ± 17.69286
C6 D168.6000 ± NA
C6 D1, Pre-dose3.4671 ± 2.09208
C6 D1, EOI47.2153 ± 22.86249
C9 D1, Pre-dose3.9596 ± 2.61261
C12 D1, Pre-dose5.6298 ± 6.30104
C18 D1, Pre-dose4.7952 ± 2.38870
C24 D1, Pre-dose4.9518 ± 2.60878
C30 D1, Pre-dose4.5167 ± 3.14142
C36 D1, Pre-dose5.3687 ± 4.47411
C42 D1, Pre-dose1.2400 ± NA
EOT (~242 weeks)2.9678 ± 7.67752
SecondaryObserved Plasma Concentrations of Belantamab Mafodotin- Total Monoclonal Antibody (mAb)

Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

Time frame:
Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; SOI + 24h on D1&2 of C1&3; D4, D8-15, D22 of C1&3; D1of C2,3,4 & 6; D2 of C3; and EOT (~242 weeks)
Reported as:
Mean · ug/mL
Observed Plasma Concentrations of Belantamab Mafodotin- Total Monoclonal Antibody (mAb)
ug/mLBelantamab Mafodotin
C1 D1, Pre-dose0.5379 ± 5.58667
C1 D1, EOI44.2483 ± 14.91713
C1 D1, SOI + 24 hours41.2999 ± 14.01003
C1 D2, SOI+ 24 hours32.7096 ± 11.17415
C1 D420.9259 ± 8.82782
C1 D8-1512.2688 ± 6.20180
C1 D225.9391 ± 4.89415
C2 D132.0000 ± 28.37622
C2 D1, Pre-dose6.2446 ± 5.39820
C2 D1, EOI51.3993 ± 21.28458
C3 D129.8917 ± 25.68839
C3 D1, Pre-dose10.4384 ± 8.69143
C3 D1, EOI54.5050 ± 22.63257
C3 D1, SOI + 24 hours48.7361 ± 20.09005
C3 D250.3500 ± 0.49497
C3 D2, SOI + 24 hours44.6118 ± 15.68169
C3 D433.1541 ± 14.83313
C3 D8-1523.7107 ± 11.14934
C3 D2213.0207 ± 8.94586
C4 D141.2000 ± 31.11270
C4 D1, Pre-dose13.1691 ± 10.19527
C4 D1, EOI57.9805 ± 20.36662
C6 D177.3000 ± NA
C6 D1, Pre-dose14.8742 ± 9.94411
C6 D1, EOI57.0211 ± 32.13534
C9 D1, Pre-dose16.1902 ± 10.42646
C12 D1, Pre-dose18.3373 ± 12.66464
C18 D1, Pre-dose24.4376 ± 15.48838
C24 D1, Pre-dose21.7079 ± 12.62491
C30 D1, Pre-dose19.8650 ± 14.43844
C36 D1, Pre-dose24.3000 ± 21.96383
C42 D1, Pre-dose4.5600 ± NA
EOT (~242 weeks)8.3097 ± 9.58575
SecondaryObserved Plasma Concentrations of Belantamab Mafodotin-Cys-mc Microtubular Inhibitor Monomethyl Auristatin-F (MMAF)

Blood samples were collected at indicated time points for pharmacokinetic analysis of belantamab mafodotin

Time frame:
Pre-dose on Day (D)1 of Cycles (C)1,2,3,4,6,9,12,18,24,30,36,42; EOI on D1 of C1,2,3, 4 & 6; D1 SOI + 2 h of C1&3; D2 SOI + 24h of C1&3; D4, D8-15, D22 of C1&3; D1 of C2,3,4,6,9,12,18,24 & 30; D2 of C3; and EOT (~242 weeks)
Reported as:
Mean · ug/mL
Observed Plasma Concentrations of Belantamab Mafodotin-Cys-mc Microtubular Inhibitor Monomethyl Auristatin-F (MMAF)
ug/mLBelantamab Mafodotin
C1 D1, Pre-dose0.00482 ± 0.048935
C1 D1, EOI0.50257 ± 0.385958
C1 D1, SOI + 2 hours0.52993 ± 0.308119
C1 D2, SOI + 24 hours1.24435 ± 0.944185
C1 D40.75975 ± 0.499179
C1 D8-150.16905 ± 0.163228
C1 D220.00236 ± 0.011322
C2 D10.27226 ± 0.372987
C2 D1, Pre-dose0.00314 ± 0.025276
C2 D1, EOI0.52055 ± 0.431549
C3 D10.24057 ± 0.283128
C3 D1, Pre-dose0.01507 ± 0.091695
C3 D1, EOI0.50649 ± 0.396744
C3 D1, SOI+ 2 hours0.50982 ± 0.338394
C3 D20.61414 ± 0.552990
C3 D2, SOI + 24 hours0.80486 ± 0.477242
C3 D40.55168 ± 0.279372
C3 D8-150.15658 ± 0.109425
C3 D220.00000 ± 0.000000
C4 D10.44550 ± 0.676984
C4 D1, Pre-dose0.01072 ± 0.046683
C4 D1, EOI0.48903 ± 0.313553
C6 D10.20500 ± 0.222222
C6 D1, Pre-dose0.00247 ± 0.011594
C6 D1, EOI0.44992 ± 0.272831
C9 D10.08611 ± 0.258333
C9 D1, Pre-dose0.04322 ± 0.289200
C12 D10.00000 ± 0.000000
C12 D1, Pre-dose0.01859 ± 0.080759
C18 D10.000000 ± 0.000000
C18 D1, Pre-dose0.00884 ± 0.025477
C24 D10.000000 ± NA
C24 D1, Pre-dose0.00000 ± 0.000000
C30 D10.000000 ± NA
C30 D1, Pre-dose0.00000 ± 0.000000
C36 D1, Pre-dose0.00000 ± 0.000000
C42 D1, Pre-dose0.00000 ± 0.00000
EOT (~242 weeks)0.03551 ± 0.114319
SecondaryNumber of Participants With Post-baseline Positive Anti-Drug Antibody (ADAs) Against Belantamab Mafodotin

Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples were tested in screening assay, and positive samples were further characterized for antibody titers.

Time frame:
Upto approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Post-baseline Positive Anti-Drug Antibody (ADAs) Against Belantamab Mafodotin
ParticipantsBelantamab Mafodotin
Number of Participants With Post-baseline Positive Anti-Drug Antibody (ADAs) Against Belantamab Mafodotin1
SecondaryTiters of ADAs Against Belantamab Mafodotin

Serum samples were collected and tested for the presence of antibodies against belantamab mafodotin . Confirmed positive ADA samples were further analyzed to obtain the titer of the antibodies. Titers of anti-drug antibodies against belantamab mafodotin is presented.

Time frame:
Up to approximately 263 weeks
Reported as:
Median · Titer
Titers of ADAs Against Belantamab Mafodotin
TiterBelantamab Mafodotin
Titers of ADAs Against Belantamab Mafodotin200 (NA to NA)
SecondaryNumber of Participants With Symptomatic Adverse Effects as Measured by the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. It includes symptomatic toxicities drawn from the CTCAE like blurred vision, chills, constipation, decreased appetite, fatigue, general pain, mouth/throat sores, nausea, nosebleed, shortness of breath, vomiting, watery eyes, cough, itchy, loose/watery stools, Numb/Tingling Hands/Feet (N/T H/F), Pain/Burning (P/B) and Problems Tasting Food/Drink (Prob Tasting F/D) . Items are scored individually on a 0 to 4 scale for severity, frequency and interference. A score of 0 indicates no symptom or interference, while higher score of 4 signify increasing severity, frequency, and interference with daily activities.

Time frame:
Up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Symptomatic Adverse Effects as Measured by the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Blurred Vision, Severity, 04031
Blurred Vision, Severity, 15032
Blurred Vision, Severity, 25021
Blurred Vision, Severity, 3438
Blurred Vision, Severity, 4242
Blurred Vision, Severity, 3+46710
Blurred Vision, Severity, Any Scale >016763
Blurred Vision, Interference, 0147
Blurred Vision, Interference, 14631
Blurred Vision, Interference, 23815
Blurred Vision, Interference, 3407
Blurred Vision, Interference, 4293
Blurred Vision, Interference, 3+46910
Blurred Vision, Interference, Any Scale >015356
Constipation, Severity, 08738
Constipation, Severity, 16222
Constipation, Severity, 22617
Constipation, Severity, 32014
Constipation, Severity, 4123
Constipation, Severity, 3+43217
Constipation, Severity, Any Scale >012056
Decreased Appetite, Severity, 05736
Decreased Appetite, Severity, 17534
Decreased Appetite, Severity, 24415
Decreased Appetite, Severity, 3235
Decreased Appetite, Severity, 484
Decreased Appetite, Severity, 3+4319
Decreased Appetite, Severity, Any Scale >015058
Decreased Appetite, Interference, 04317
Decreased Appetite, Interference, 15120
Decreased Appetite, Interference, 22913
Decreased Appetite, Interference, 3195
Decreased Appetite, Interference, 483
Decreased Appetite, Interference, 3+4278
Decreased Appetite, Interference, Any Scale >010741
Fatigue, Severity, 0198
Fatigue, Severity, 15021
Fatigue, Severity, 27735
Fatigue, Severity, 34219
Fatigue, Severity, 41911
Fatigue, Severity, 3+46130
Fatigue, Severity, Any Scale >018886
Fatigue, Interference, 094
Fatigue, Interference, 14626
Fatigue, Interference, 26425
Fatigue, Interference, 34417
Fatigue, Interference, 42514
Fatigue, Interference, 3+46931
Fatigue, Interference, Any Scale >017982
General Pain, Frequency, 08546
General Pain, Frequency, 16126
General Pain, Frequency, 23516
General Pain, Frequency, 3175
General Pain, Frequency, 491
General Pain, Frequency, 3+4266
General Pain, Frequency, Any Scale >012248
General Pain, Severity, 0143
General Pain, Severity, 15926
General Pain, Severity, 22815
General Pain, Severity, 3183
General Pain, Severity, 431
General Pain, Severity, 3+4214
General Pain, Severity, Any Scale >010845
General Pain, Interference, 02215
General Pain, Interference, 15018
General Pain, Interference, 21910
General Pain, Interference, 3141
General Pain, Interference, 431
General Pain, Interference, 3+4172
General Pain, Interference, Any Scale >08630
Mouth/Throat Sores, Severity, 013258
Mouth/Throat Sores, Severity, 14420
Mouth/Throat Sores, Severity, 22211
Mouth/Throat Sores, Severity, 364
Mouth/Throat Sores, Severity, 431
Mouth/Throat Sores, Severity, 3+495
Mouth/Throat Sores, Severity, Any Scale >07536
Mouth/Throat Sores, Interference, 02315
Mouth/Throat Sores, Interference, 13314
Mouth/Throat Sores, Interference, 2102
Mouth/Throat Sores, Interference, 353
Mouth/Throat Sores, Interference, 442
Mouth/Throat Sores, Interference, 3+495
Mouth/Throat Sores, Interference, Any Scale >05221
Nausea, Frequency, 09754
Nausea, Frequency, 15423
Nausea, Frequency, 23213
Nausea, Frequency, 3174
Nausea, Frequency, 470
Nausea, Frequency, 3+4244
Nausea, Frequency, Any Scale >011040
Nausea, Severity, 0108
Nausea, Severity, 15519
Nausea, Severity, 2269
Nausea, Severity, 3174
Nausea, Severity, 420
Nausea, Severity, 3+4194
Nausea, Severity, Any Scale >010032
Nosebleeds, Frequency, 012774
Nosebleeds, Frequency, 15115
Nosebleeds, Frequency, 2203
Nosebleeds, Frequency, 361
Nosebleeds, Frequency, 431
Nosebleeds, Frequency, 3+492
Nosebleeds, Frequency, Any Scale >08020
Nosebleeds, Severity, 0126
Nosebleeds, Severity, 14612
Nosebleeds, Severity, 2141
Nosebleeds, Severity, 351
Nosebleeds, Severity, 430
Nosebleeds, Severity, 3+481
Nosebleeds, Severity, Any Scale >06814
Shivering/Shaking Chills, Frequency, 010243
Shivering/Shaking Chills, Frequency, 15225
Shivering/Shaking Chills, Frequency, 23412
Shivering/Shaking Chills, Frequency, 31713
Shivering/Shaking Chills, Frequency, 421
Shivering/Shaking Chills, Frequency, 3+41914
Shivering/Shaking Chills, Frequency, Any Scale >010551
Shivering/Shaking Chills, Severity, 0116
Shivering/Shaking Chills, Severity, 15923
Shivering/Shaking Chills, Severity, 22511
Shivering/Shaking Chills, Severity, 3910
Shivering/Shaking Chills, Severity, 411
Shivering/Shaking Chills, Severity, 3+41011
Shivering/Shaking Chills, Severity, Any Scale >09445
Shortness of Breath, Severity, 06624
Shortness of Breath, Severity, 16832
Shortness of Breath, Severity, 24522
Shortness of Breath, Severity, 3209
Shortness of Breath, Severity, 487
Shortness of Breath, Severity, 3+42816
Shortness of Breath, Severity, Any Scale >014170
Vomiting, Frequency, 015881
Vomiting, Frequency, 1277
Vomiting, Frequency, 2124
Vomiting, Frequency, 3102
Vomiting, Frequency, 400
Vomiting, Frequency, 3+4102
Vomiting, Frequency, Any Scale >04913
Vomiting, Severity, 051
Vomiting, Severity, 1236
Vomiting, Severity, 2145
Vomiting, Severity, 361
Vomiting, Severity, 410
Vomiting, Severity, 3+471
Vomiting, Severity, Any Scale >04412
Watery Eyes, Severity, 07641
Watery Eyes, Severity, 16039
Watery Eyes, Severity, 24211
Watery Eyes, Severity, 3273
Watery Eyes, Severity, 420
Watery Eyes, Severity, 3+4293
Watery Eyes, Severity, Any Scale >013153
Watery Eyes, Interference, 01516
Watery Eyes, Interference, 16127
Watery Eyes, Interference, 2327
Watery Eyes, Interference, 3182
Watery Eyes, Interference, 451
Watery Eyes, Interference, 3+4233
Watery Eyes, Interference, Any Scale >011637
Cough, Severity, 010343
Cough, Severity, 16928
Cough, Severity, 21716
Cough, Severity, 3156
Cough, Severity, 431
Cough, Severity, 3+4187
Cough, Severity, Any Scale >010451
Cough, Interference, 03216
Cough, Interference, 14418
Cough, Interference, 22010
Cough, Interference, 347
Cough, Interference, 440
Cough, Interference, 3+487
Cough, Interference, Any Scale >07235
Itchy, Severity, 09852
Itchy, Severity, 17524
Itchy, Severity, 22415
Itchy, Severity, 363
Itchy, Severity, 440
Itchy, Severity, 3+4103
Itchy, Severity, Any Scale >010942
Loose/Watery Stools, Frequency, 08640
Loose/Watery Stools, Frequency, 14827
Loose/Watery Stools, Frequency, 23714
Loose/Watery Stools, Frequency, 3229
Loose/Watery Stools, Frequency, 4144
Loose/Watery Stools, Frequency, 3+43613
Loose/Watery Stools, Freq., Any Scale >012154
N/T H/F, Severity, 05026
N/T H/F, Severity, 17025
N/T H/F, Severity, 25431
N/T H/F, Severity, 32311
N/T H/F, Severity, 4101
N/T H/F, Severity, 3+43312
N/T H/F, Severity, Any Scale >015768
N/T H/F, Interference, 03412
N/T H/F, Interference, 15727
N/T H/F, Interference, 24320
N/T H/F, Interference, 3135
N/T H/F, Interference, 4104
N/T H/F, Interference, 3+4239
N/T H/F, Interference, Any Scale >012356
P/B Urination, Severity, 013568
P/B Urination, Severity, 14917
P/B Urination, Severity, 2186
P/B Urination, Severity, 342
P/B Urination, Severity, 411
P/B Urination, Severity, 3+453
P/B Urination, Severity, Any Scale >07226
Prob Tasting F/D, Severity, 010851
Prob Tasting F/D, Severity, 15724
Prob Tasting F/D, Severity, 2249
Prob Tasting F/D, Severity, 3156
Prob Tasting F/D, Severity, 434
Prob Tasting F/D, Severity, 3+41810
Prob Tasting F/D, Severity, Any Scale >09943
SecondaryChange From Baseline (CFB) in Ocular Surface Disease Index (OSDI) Total Score

OSDI is 12-item patient-reported outcomes questionnaire designed to provide rapid assessment of range of ocular surface symptoms, including symptoms related to chronic dry eye, severity, and impact on patient's ability to function. In addition to an overall score, there are three subscales of OSDI: ocular symptoms, vision-related function, and environmental triggers. OSDI items are scored on a 0 to 4 Likert-type scale, where 0 = None of the time and 4 = All of the time. Total OSDI score = (\[sum of scores for all questions answered×100\]/\[total number of questions answered×4\]). Subscale scores are computed similarly with only questions from each subscale used to generate its own score. Any subscales analyzed separately would also have a maximum possible score of 100. A score of 100=to complete disability, while a score of 0=to no disability. Decrease in score from baseline means improvement

Time frame:
Baseline (Day 1) and Up to approximately 263 weeks
Reported as:
Mean · Scores on Scale
Change From Baseline (CFB) in Ocular Surface Disease Index (OSDI) Total Score
Scores on ScaleBelantamab MafodotinPomalidomide Plus Dexamethasone
CFB to Week 42.59 ± 17.4761.41 ± 12.547
CFB to Week 713.07 ± 25.9891.66 ± 14.990
CFB to Week 1015.29 ± 27.8432.66 ± 19.075
CFB to Week 1313.38 ± 26.0894.19 ± 16.918
CFB to Week 1613.26 ± 26.1843.11 ± 18.073
CFB to Week 1910.80 ± 26.9483.40 ± 20.072
CFB to Week 2211.90 ± 25.8445.07 ± 20.162
CFB to Week 2510.80 ± 22.4113.04 ± 15.127
CFB to Week 2810.00 ± 24.2922.42 ± 16.637
CFB to Week 3111.59 ± 24.2170.10 ± 14.473
CFB to Week 3412.78 ± 24.293-3.77 ± 16.175
CFB to Week 3711.12 ± 25.434-4.01 ± 13.960
CFB to Week 4011.94 ± 29.6806.25 ± 30.021
CFB to Week 439.94 ± 26.511-2.57 ± 13.078
CFB to Week 4613.39 ± 23.682-1.05 ± 10.973
CFB to Week 499.43 ± 23.900-1.58 ± 10.344
CFB to Week 528.50 ± 23.103-3.39 ± 11.210
CFB to Week 556.71 ± 23.217-2.40 ± 11.789
CFB to Week 588.06 ± 27.288-1.71 ± 11.305
CFB to Week 619.86 ± 24.993-1.46 ± 13.508
CFB to Week 6411.15 ± 27.558-0.90 ± 11.579
CFB to Week 678.72 ± 25.841-1.08 ± 12.042
CFB to Week 705.82 ± 25.5802.21 ± 7.068
CFB to Week 7310.00 ± 27.5060.42 ± 12.045
CFB to Week 7613.64 ± 25.4044.93 ± 10.105
CFB to Week 7911.45 ± 29.2930.33 ± 10.061
CFB to Week 827.54 ± 27.703-1.60 ± 10.799
CFB to Week 859.21 ± 30.044-1.45 ± 14.926
CFB to Week 888.16 ± 29.508-1.09 ± 12.537
CFB to Week 9114.39 ± 35.202-1.40 ± 15.058
CFB to Week 947.34 ± 28.796-1.92 ± 17.782
CFB to Week 9712.80 ± 19.9920.98 ± 15.164
CFB to Week 10011.67 ± 28.1301.21 ± 14.782
CFB to Week 1037.19 ± 26.707-0.09 ± 18.537
CFB to Week 1065.40 ± 26.244-0.90 ± 20.060
CFB to Week 1094.79 ± 25.1593.11 ± 15.098
CFB to Week 1123.31 ± 23.345-0.70 ± 18.898
CFB to Week 1153.20 ± 23.7635.18 ± 14.995
CFB to Week 1186.93 ± 28.8763.78 ± 22.276
CFB to Week 1214.59 ± 30.6640.83 ± 21.583
CFB to Week 1246.22 ± 30.0722.71 ± 25.931
CFB to Week 1270.62 ± 27.8623.59 ± 20.142
CFB to Week 130-0.38 ± 26.198-0.76 ± 26.377
CFB to Week 1334.17 ± 31.7243.31 ± 27.578
CFB to Week 1364.67 ± 30.314-1.76 ± 28.117
CFB to Week 13912.31 ± 24.9850.47 ± 26.057
CFB to Week 1421.71 ± 28.995-0.21 ± 37.083
CFB to Week 14510.39 ± 20.291-4.03 ± 25.715
CFB to Week 1516.42 ± 29.284-0.25 ± 30.276
CFB to Week 1545.96 ± 31.2730.93 ± 28.401
CFB to Week 1571.62 ± 30.352-5.42 ± 35.933
CFB to Week 1605.59 ± 34.252-7.85 ± 32.500
CFB to Week 1632.02 ± 31.500-1.94 ± 42.950
CFB to Week 1667.78 ± 12.6603.89 ± 29.360
CFB to Week 1692.43 ± 32.178-2.78 ± 39.240
CFB to Week 172-5.88 ± 33.448-11.57 ± 30.185
CFB to Week 1756.06 ± 19.2695.28 ± 37.364
CFB to Week 1782.83 ± 41.1011.62 ± 30.108
CFB to Week 181-6.07 ± 32.5701.99 ± 42.043
CFB to Week 184-1.11 ± 44.7660.19 ± 32.223
CFB to Week 1870.73 ± 16.11143.33 ± 15.321
CFB to Week 193-16.07 ± 43.9564.93 ± 37.846
CFB to Week 196-9.58 ± 38.6559.44 ± 44.098
CFB to Week 199-6.96 ± 20.187-5.97 ± 23.810
CFB to Week 202-11.72 ± 40.286-3.01 ± 9.857
CFB to Week 208-14.13 ± 40.96511.25 ± 15.910
CFB to Week 211-19.11 ± 47.9908.75 ± 12.374
CFB to Week 21413.61 ± 16.8815.00 ± 7.071
CFB to Week 217-48.96 ± 69.2387.50 ± 10.607
CFB to Week 220-9.29 ± 17.07111.11 ± 15.713
CFB to Week 223-31.84 ± 47.5698.75 ± 12.374
CFB to Week 226-42.79 ± 50.1107.50 ± NA
CFB to Week 229-14.38 ± 20.32915.00 ± NA
CFB to Week 232-42.10 ± 48.96610.00 ± NA
CFB to Week 235-50.00 ± 70.71120.00 ± NA
CFB to Week 238—15.00 ± NA
CFB to LFU (~263 weeks)2.81 ± 21.24515.74 ± 9.755
CFB to EOT (~242 weeks)11.77 ± 25.2646.08 ± 18.132
SecondaryChange From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score.

The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], emotional functioning \[EF\] cognitive functioning \[CF\] and social functioning \[SF\]), three symptom scales (fatigue, nausea/vomiting \[N/V\] and pain), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (dyspnea, insomnia, appetite loss \[AL\], constipation, diarrhea and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238, End of Treatment (~242 weeks) and Follow up (~ 263 weeks)
Reported as:
Mean · Scores on Scale
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) Score.
Scores on ScaleBelantamab MafodotinPomalidomide Plus Dexamethasone
GHS, CFB to Week 40.47 ± 20.619-3.11 ± 23.198
GHS, CFB to Week 70.57 ± 20.052-2.14 ± 23.279
GHS, CFB to Week 101.95 ± 20.585-2.18 ± 24.794
GHS, CFB to Week 130.98 ± 19.935-3.30 ± 27.034
GHS, CFB to Week 161.73 ± 23.337-3.40 ± 26.870
GHS, CFB to Week 194.55 ± 23.2311.50 ± 25.627
GHS, CFB to Week 222.52 ± 23.6051.79 ± 25.868
GHS, CFB to Week 252.99 ± 25.276-1.23 ± 25.470
GHS, CFB to Week 285.10 ± 24.6700.00 ± 23.570
GHS, CFB to Week 315.02 ± 24.1500.51 ± 24.379
GHS, CFB to Week 347.31 ± 23.3216.00 ± 24.594
GHS, CFB to Week 377.00 ± 27.8823.00 ± 24.400
GHS, CFB to Week 408.33 ± 24.6963.67 ± 29.372
GHS, CFB to Week 437.50 ± 29.8336.35 ± 25.400
GHS, CFB to Week 467.55 ± 26.13010.94 ± 28.661
GHS, CFB to Week 4910.03 ± 24.27011.84 ± 25.657
GHS, CFB to Week 5212.70 ± 24.5416.25 ± 26.196
GHS, CFB to Week 559.17 ± 26.4733.51 ± 29.307
GHS, CFB to Week 588.77 ± 30.1056.48 ± 27.350
GHS, CFB to Week 6111.93 ± 27.2478.33 ± 29.149
GHS, CFB to Week 6410.46 ± 26.71110.00 ± 30.732
GHS, CFB to Week 6710.17 ± 25.49313.54 ± 25.797
GHS, CFB to Week 709.67 ± 26.1568.97 ± 25.563
GHS, CFB to Week 739.76 ± 29.0428.33 ± 27.095
GHS, CFB to Week 7613.69 ± 24.68111.11 ± 30.807
GHS, CFB to Week 7911.51 ± 25.76410.56 ± 25.289
GHS, CFB to Week 8210.66 ± 26.68411.67 ± 27.960
GHS, CFB to Week 858.56 ± 29.8206.41 ± 27.879
GHS, CFB to Week 8811.34 ± 25.2109.62 ± 28.635
GHS, CFB to Week 919.68 ± 27.8833.57 ± 33.923
GHS, CFB to Week 9411.34 ± 28.6024.17 ± 36.670
GHS, CFB to Week 9712.22 ± 27.8319.85 ± 29.302
GHS, CFB to Week 1009.76 ± 27.3030.00 ± 29.397
GHS, CFB to Week 10314.22 ± 27.6412.78 ± 29.756
GHS, CFB to Week 10615.40 ± 26.1974.76 ± 29.603
GHS, CFB to Week 10913.97 ± 27.8837.29 ± 29.017
GHS, CFB to Week 11511.39 ± 25.1893.13 ± 32.409
GHS, CFB to Week 1189.17 ± 25.4608.33 ± 26.352
GHS, CFB to Week 1218.67 ± 22.1116.25 ± 26.633
GHS, CFB to Week 12410.58 ± 24.67113.89 ± 26.176
GHS, CFB to Week 12711.22 ± 26.66112.50 ± 29.698
GHS, CFB to Week 13013.00 ± 26.25115.00 ± 27.889
GHS, CFB to Week 13310.76 ± 27.63611.11 ± 28.219
GHS, CFB to Week 13913.10 ± 27.71011.11 ± 30.581
GHS, CFB to Week 1429.85 ± 23.51918.75 ± 30.713
GHS, CFB to Week 1486.14 ± 29.76818.75 ± 30.713
GHS, CFB to Week 1517.94 ± 25.20418.75 ± 30.713
GHS, CFB to Week 1549.21 ± 29.25220.83 ± 30.807
GHS, CFB to Week 1574.41 ± 29.33316.67 ± 41.667
GHS, CFB to Week 1607.87 ± 22.41019.44 ± 37.577
GHS, CFB to Week 16311.57 ± 23.76716.67 ± 41.667
GHS, CFB to Week 16612.78 ± 27.43416.67 ± 41.667
GHS, CFB to Week 16912.25 ± 29.62716.67 ± 46.398
GHS, CFB to Week 17212.82 ± 32.20619.44 ± 37.577
GHS, CFB to Week 17516.67 ± 30.36013.89 ± 45.896
GHS, CFB to Week 17810.71 ± 32.26325.00 ± 33.333
GHS, CFB to Week 18113.10 ± 35.46316.67 ± 41.667
GHS, CFB to Week 1849.09 ± 30.83416.67 ± 41.667
GHS, CFB to Week 1872.78 ± 31.45812.50 ± 64.818
GHS, CFB to Week 1935.95 ± 28.34716.67 ± 41.667
GHS, CFB to Week 19627.08 ± 30.45613.89 ± 45.896
GHS, CFB to Week 1995.95 ± 34.2638.33 ± 54.645
GHS, CFB to Week 20218.52 ± 29.10019.44 ± 37.577
GHS, CFB to Week 20819.05 ± 36.2330.00 ± 23.570
GHS, CFB to Week 21111.67 ± 38.006-4.17 ± 29.463
GHS, CFB to Week 21422.22 ± 45.8960.00 ± 23.570
GHS, CFB to Week 2170.00 ± 0.0000.00 ± 23.570
GHS, CFB to Week 220-4.17 ± 29.463-8.33 ± 35.355
GHS, CFB to Week 223-4.17 ± 19.8370.00 ± 23.570
GHS, CFB to Week 2262.78 ± 17.347-16.67 ± NA
GHS, CFB to Week 22916.67 ± 23.570-25.00 ± NA
GHS, CFB to Week 2325.56 ± 25.459-33.33 ± NA
GHS, CFB to Week 235-8.33 ± 11.785-33.33 ± NA
GHS, CFB to Week 238—-33.33 ± NA
GHS, CFB to EOT (~242 weeks)-7.35 ± 27.192-12.88 ± 24.468
GHS, CFB to LFU (~263 weeks)-0.60 ± 26.749-0.83 ± 22.114
PF, CFB to Week 40.68 ± 17.9720.78 ± 14.129
PF, CFB to Week 73.04 ± 19.097-0.60 ± 18.460
PF, CFB to Week 101.59 ± 18.0110.00 ± 19.437
PF, CFB to Week 132.84 ± 17.088-3.22 ± 16.004
PF, CFB to Week 161.95 ± 19.751-0.74 ± 15.790
PF, CFB to Week 193.07 ± 21.0291.36 ± 16.264
PF, CFB to Week 222.32 ± 19.0750.63 ± 16.969
PF, CFB to Week 253.36 ± 18.0970.59 ± 12.322
PF, CFB to Week 284.58 ± 18.3901.52 ± 18.371
PF, CFB to Week 315.93 ± 17.4343.84 ± 16.752
PF, CFB to Week 344.63 ± 20.0812.67 ± 9.623
PF, CFB to Week 375.28 ± 20.3100.80 ± 10.597
PF, CFB to Week 408.38 ± 18.361-0.80 ± 10.941
PF, CFB to Week 437.21 ± 20.266-0.32 ± 15.126
PF, CFB to Week 467.60 ± 20.4812.22 ± 16.330
PF, CFB to Week 498.82 ± 19.4783.33 ± 9.750
PF, CFB to Week 5210.55 ± 17.1443.92 ± 12.203
PF, CFB to Week 556.19 ± 20.4495.26 ± 10.081
PF, CFB to Week 586.28 ± 21.4600.99 ± 11.285
PF, CFB to Week 619.37 ± 19.552-2.59 ± 15.700
PF, CFB to Week 649.40 ± 21.5392.67 ± 12.293
PF, CFB to Week 677.82 ± 23.1136.25 ± 13.437
PF, CFB to Week 707.02 ± 21.1314.10 ± 17.541
PF, CFB to Week 738.83 ± 21.3644.44 ± 12.258
PF, CFB to Week 766.88 ± 19.2415.33 ± 18.379
PF, CFB to Week 7910.32 ± 19.7356.19 ± 19.649
PF, CFB to Week 828.78 ± 20.8936.67 ± 15.327
PF, CFB to Week 8511.83 ± 19.5284.10 ± 17.114
PF, CFB to Week 8810.00 ± 21.8226.15 ± 13.183
PF, CFB to Week 919.19 ± 21.906-0.95 ± 17.899
PF, CFB to Week 9411.11 ± 23.798-6.67 ± 36.670
PF, CFB to Week 979.11 ± 15.2110.61 ± 15.335
PF, CFB to Week 10614.34 ± 22.9811.90 ± 22.015
PF, CFB to Week 10011.62 ± 21.8341.33 ± 21.728
PF, CFB to Week 1039.80 ± 18.0713.70 ± 17.985
PF, CFB to Week 10914.31 ± 21.6575.83 ± 17.973
PF, CFB to Week 11213.95 ± 21.6834.76 ± 17.518
PF, CFB to Week 11511.33 ± 19.5861.67 ± 11.127
PF, CFB to Week 1187.78 ± 21.873-0.83 ± 21.510
PF, CFB to Week 1217.47 ± 19.4676.67 ± 17.457
PF, CFB to Week 12411.54 ± 22.43510.00 ± 22.211
PF, CFB to Week 12711.28 ± 21.2314.44 ± 18.698
PF, CFB to Week 13014.13 ± 22.4704.00 ± 24.766
PF, CFB to Week 13312.50 ± 21.8304.44 ± 23.727
PF, CFB to Week 13615.56 ± 24.7956.67 ± 20.000
PF, CFB to Week 13916.19 ± 23.6246.67 ± 23.851
PF, CFB to Week 14212.42 ± 20.3988.33 ± 26.317
PF, CFB to Week 1454.07 ± 25.9859.33 ± 22.901
PF, CFB to Week 14811.23 ± 25.5368.33 ± 21.344
PF, CFB to Week 1516.35 ± 25.16410.00 ± 22.771
PF, CFB to Week 1548.77 ± 23.8368.33 ± 22.690
PF, CFB to Week 1576.67 ± 24.8332.22 ± 23.413
PF, CFB to Week 1602.96 ± 15.3776.67 ± 30.551
PF, CFB to Week 1636.30 ± 26.01913.33 ± 23.094
PF, CFB to Week 1669.78 ± 27.70213.33 ± 29.059
PF, CFB to Week 1695.88 ± 29.71011.11 ± 25.240
PF, CFB to Week 17211.79 ± 32.67713.33 ± 23.094
PF, CFB to Week 17517.22 ± 29.87613.33 ± 23.094
PF, CFB to Week 1788.10 ± 32.25715.56 ± 26.943
PF, CFB to Week 18111.90 ± 30.0638.89 ± 21.430
PF, CFB to Week 18411.52 ± 31.56513.33 ± 35.277
PF, CFB to Week 1878.15 ± 37.82720.00 ± 47.140
PF, CFB to Week 19012.00 ± 33.67213.33 ± 35.277
PF, CFB to Week 1930.95 ± 11.81913.33 ± 35.277
PF, CFB to Week 19619.17 ± 38.12116.11 ± 32.332
PF, CFB to Week 1997.62 ± 40.81211.11 ± 37.908
PF, CFB to Week 20218.52 ± 36.63311.11 ± 31.505
PF, CFB to Week 20525.71 ± 40.264-2.50 ± 3.536
PF, CFB to Week 20822.86 ± 39.974-6.67 ± 9.428
PF, CFB to Week 21110.67 ± 29.288-10.00 ± 14.142
PF, CFB to Week 21411.11 ± 31.505-6.67 ± 9.428
PF, CFB to Week 2170.00 ± 0.000-6.67 ± 9.428
PF, CFB to Week 2200.00 ± 28.284-6.67 ± 9.428
PF, CFB to Week 2233.33 ± 22.1110.00 ± 0.000
PF, CFB to Week 2266.67 ± 11.547-6.67 ± NA
PF, CFB to Week 22916.67 ± 23.570-6.67 ± NA
PF, CFB to Week 23211.11 ± 19.245-13.33 ± NA
PF, CFB to Week 2350.00 ± 0.000-20.00 ± NA
PF, CFB to Week 238—-6.67 ± NA
PF, CFB to EOT (~242 weeks)-9.34 ± 25.270-9.80 ± 23.453
PF, CFB to LFU (~263 weeks)-6.96 ± 27.7113.00 ± 26.796
RF, CFB to Week 40.85 ± 24.770-4.42 ± 26.555
RF, CFB to Week 7-0.11 ± 26.078-1.08 ± 27.880
RF, CFB to Week 10-0.91 ± 25.897-3.59 ± 28.941
RF, CFB to Week 13-0.61 ± 22.681-5.46 ± 28.337
RF, CFB to Week 16-1.27 ± 31.069-1.23 ± 24.412
RF, CFB to Week 19-0.35 ± 28.0951.67 ± 25.028
RF, CFB to Week 22-1.23 ± 27.531-1.59 ± 26.496
RF, CFB to Week 253.33 ± 27.844-3.65 ± 29.248
RF, CFB to Week 283.37 ± 29.1310.00 ± 27.116
RF, CFB to Week 313.63 ± 28.382-1.01 ± 25.324
RF, CFB to Week 341.60 ± 30.8283.33 ± 23.074
RF, CFB to Week 372.90 ± 33.4500.00 ± 23.074
RF, CFB to Week 405.48 ± 31.4340.00 ± 25.909
RF, CFB to Week 435.00 ± 32.272-4.76 ± 30.342
RF, CFB to Week 465.99 ± 30.1921.04 ± 33.593
RF, CFB to Week 499.38 ± 28.464-0.88 ± 20.393
RF, CFB to Week 529.68 ± 26.7473.33 ± 25.706
RF, CFB to Week 555.65 ± 29.460-0.88 ± 20.393
RF, CFB to Week 586.14 ± 30.150-10.19 ± 28.087
RF, CFB to Week 617.19 ± 28.530-2.78 ± 25.082
RF, CFB to Week 646.86 ± 29.283-1.11 ± 22.242
RF, CFB to Week 678.67 ± 29.4011.04 ± 25.436
RF, CFB to Week 707.67 ± 27.605-1.28 ± 24.019
RF, CFB to Week 733.66 ± 30.621-5.56 ± 27.936
RF, CFB to Week 764.37 ± 26.560-7.78 ± 28.776
RF, CFB to Week 798.73 ± 27.358-3.33 ± 27.603
RF, CFB to Week 8211.63 ± 28.9901.11 ± 31.159
RF, CFB to Week 859.91 ± 24.6772.56 ± 20.237
RF, CFB to Week 889.72 ± 27.1312.56 ± 25.318
RF, CFB to Week 916.76 ± 26.487-8.33 ± 35.656
RF, CFB to Week 947.87 ± 29.677-9.72 ± 40.488
RF, CFB to Week 9713.33 ± 24.9143.03 ± 33.181
RF, CFB to Week 10013.81 ± 26.961-10.00 ± 35.312
RF, CFB to Week 10312.25 ± 29.102-5.56 ± 28.868
RF, CFB to Week 10616.16 ± 29.013-7.14 ± 37.090
RF, CFB to Week 10917.65 ± 25.604-4.17 ± 24.801
RF, CFB to Week 11217.22 ± 31.405-2.38 ± 17.817
RF, CFB to Week 11513.33 ± 29.8140.00 ± 25.198
RF, CFB to Week 11810.00 ± 29.556-2.08 ± 25.877
RF, CFB to Week 1218.00 ± 31.593-4.17 ± 24.801
RF, CFB to Week 12414.74 ± 33.44211.11 ± 36.004
RF, CFB to Week 12712.18 ± 31.1128.33 ± 27.386
RF, CFB to Week 13015.33 ± 30.01512.50 ± 36.956
RF, CFB to Week 13312.50 ± 31.5658.33 ± 29.345
RF, CFB to Week 13610.32 ± 32.26516.67 ± 33.333
RF, CFB to Week 13910.32 ± 30.49411.11 ± 34.427
RF, CFB to Week 14212.12 ± 30.07112.50 ± 36.956
RF, CFB to Week 1457.41 ± 28.13513.33 ± 27.386
RF, CFB to Week 14810.53 ± 27.33620.83 ± 36.956
RF, CFB to Week 1517.94 ± 35.98612.50 ± 28.464
RF, CFB to Week 15410.53 ± 35.22916.67 ± 30.429
RF, CFB to Week 1572.94 ± 30.18211.11 ± 34.694
RF, CFB to Week 160-1.85 ± 24.84522.22 ± 53.576
RF, CFB to Week 1634.63 ± 33.72611.11 ± 34.694
RF, CFB to Week 1668.89 ± 33.84525.00 ± 35.355
RF, CFB to Week 16913.73 ± 32.93316.67 ± 28.868
RF, CFB to Week 17217.95 ± 28.43216.67 ± 44.096
RF, CFB to Week 17515.28 ± 37.24022.22 ± 53.576
RF, CFB to Week 1785.95 ± 35.57116.67 ± 28.868
RF, CFB to Week 18114.29 ± 33.24211.11 ± 34.694
RF, CFB to Week 18410.61 ± 39.63216.67 ± 44.096
RF, CFB to Week 1877.41 ± 50.07733.33 ± 70.711
RF, CFB to Week 19010.00 ± 37.84322.22 ± 53.576
RF, CFB to Week 1934.76 ± 24.93422.22 ± 53.576
RF, CFB to Week 19625.00 ± 37.79622.22 ± 53.576
RF, CFB to Week 1999.52 ± 46.00444.096 ± 16.67
RF, CFB to Week 20216.67 ± 37.26822.22 ± 53.576
RF, CFB to Week 20528.57 ± 48.795-16.67 ± 23.570
RF, CFB to Week 20826.19 ± 47.000-8.33 ± 11.785
RF, CFB to Week 21120.00 ± 44.721-8.33 ± 11.785
RF, CFB to Week 21416.67 ± 44.096-8.33 ± 11.785
RF, CFB to Week 2170.00 ± 0.000-8.33 ± 11.785
RF, CFB to Week 2200.00 ± 47.140-8.33 ± 11.785
RF, CFB to Week 2238.33 ± 41.944-8.33 ± 11.785
RF, CFB to Week 22616.67 ± 28.86816.67 ± NA
RF, CFB to Week 22933.33 ± 47.140-16.67 ± NA
RF, CFB to Week 23216.67 ± 28.868-16.67 ± NA
RF, CFB to Week 2350.00 ± 0.000-16.67 ± NA
RF, CFB to Week 238—-16.67 ± NA
RF, CFB to EOT (~242 weeks)-12.57 ± 32.169-11.11 ± 33.119
RF, CFB to LFU (~263 weeks)-7.60 ± 31.072-1.67 ± 36.635
EF, CFB to Week 40.28 ± 17.941-0.10 ± 17.543
EF, CFB to Week 70.25 ± 20.1233.31 ± 17.733
EF, CFB to Week 101.29 ± 17.3512.31 ± 17.709
EF, CFB to Week 132.85 ± 19.1190.86 ± 20.808
EF, CFB to Week 161.35 ± 22.1422.47 ± 17.853
EF, CFB to Week 192.66 ± 21.4686.17 ± 20.119
EF, CFB to Week 220.26 ± 18.5722.78 ± 17.718
EF, CFB to Week 251.09 ± 17.784-2.21 ± 19.817
EF, CFB to Week 28-1.18 ± 17.6381.67 ± 21.936
EF, CFB to Week 31-0.21 ± 15.6612.27 ± 18.549
EF, CFB to Week 341.07 ± 15.1061.33 ± 12.883
EF, CFB to Week 370.85 ± 17.858-2.00 ± 15.077
EF, CFB to Week 400.60 ± 15.883-3.00 ± 17.821
EF, CFB to Week 432.74 ± 20.000-1.19 ± 19.236
EF, CFB to Week 463.52 ± 17.556-1.04 ± 16.066
EF, CFB to Week 493.78 ± 17.2470.15 ± 12.846
EF, CFB to Week 522.91 ± 17.7192.08 ± 2.08
EF, CFB to Week 552.36 ± 16.0980.00 ± 15.466
EF, CFB to Week 581.90 ± 20.7750.46 ± 18.846
EF, CFB to Week 615.39 ± 13.927-3.70 ± 11.862
EF, CFB to Week 644.08 ± 15.6685.00 ± 9.860
EF, CFB to Week 671.33 ± 13.295-1.04 ± 16.066
EF, CFB to Week 703.50 ± 14.6861.92 ± 11.860
EF, CFB to Week 731.22 ± 14.8561.11 ± 16.627
EF, CFB to Week 762.38 ± 16.6960.56 ± 14.929
EF, CFB to Week 792.78 ± 16.2202.22 ± 14.929
EF, CFB to Week 822.38 ± 17.0970.56 ± 14.929
EF, CFB to Week 852.93 ± 15.862-4.49 ± 16.533
EF, CFB to Week 88-2.39 ± 20.3382.56 ± 7.124
EF, CFB to Week 912.70 ± 16.673-3.57 ± 20.338
EF, CFB to Week 942.78 ± 14.2260.69 ± 9.704
EF, CFB to Week 971.94 ± 18.5290.00 ± 15.811
EF, CFB to Week 1004.05 ± 15.175-0.83 ± 10.722
EF, CFB to Week 1032.70 ± 18.9942.78 ± 9.317
EF, CFB to Week 1061.77 ± 16.3723.57 ± 8.133
EF, CFB to Week 1092.94 ± 18.3364.17 ± 8.909
EF, CFB to Week 1124.02 ± 14.3685.95 ± 6.299
EF, CFB to Week 1155.56 ± 14.0702.08 ± 15.905
EF, CFB to Week 1181.67 ± 17.0082.08 ± 9.708
EF, CFB to Week 1211.67 ± 15.5905.21 ± 8.839
EF, CFB to Week 1241.60 ± 17.4838.33 ± 13.944
EF, CFB to Week 1272.24 ± 15.3760.00 ± 10.541
EF, CFB to Week 1303.67 ± 13.6258.33 ± 8.333
EF, CFB to Week 133-1.04 ± 17.430-1.39 ± 11.076
EF, CFB to Week 1360.79 ± 15.5690.00 ± 11.785
EF, CFB to Week 1391.98 ± 14.8850.00 ± 9.129
EF, CFB to Week 1421.52 ± 14.9156.25 ± 7.979
EF, CFB to Week 1453.24 ± 16.2041.67 ± 9.129
EF, CFB to Week 1480.00 ± 14.1646.25 ± 7.979
EF, CFB to Week 1510.00 ± 17.4802.08 ± 10.486
EF, CFB to Week 154-2.19 ± 19.2134.17 ± 8.333
EF, CFB to Week 157-4.90 ± 13.8385.56 ± 9.623
EF, CFB to Week 160-5.56 ± 17.62011.11 ± 9.623
EF, CFB to Week 163-1.85 ± 16.8025.56 ± 9.623
EF, CFB to Week 1662.22 ± 15.8955.56 ± 9.623
EF, CFB to Week 1691.47 ± 15.0915.56 ± 9.623
EF, CFB to Week 1723.21 ± 13.8358.33 ± 8.333
EF, CFB to Week 1755.56 ± 14.7945.56 ± 9.623
EF, CFB to Week 178-1.79 ± 17.35111.11 ± 9.623
EF, CFB to Week 1812.38 ± 17.7320.00 ± 16.667
EF, CFB to Week 1841.52 ± 17.8028.33 ± 8.333
EF, CFB to Week 187-6.48 ± 19.4444.17 ± 5.893
EF, CFB to Week 190-11.11 ± 28.8685.56 ± 9.623
EF, CFB to Week 1935.95 ± 9.2728.33 ± 8.333
EF, CFB to Week 1968.33 ± 7.71511.11 ± 9.623
EF, CFB to Week 199-2.38 ± 10.4465.56 ± 9.623
EF, CFB to Week 2026.48 ± 12.3458.33 ± 8.333
EF, CFB to Week 20511.90 ± 15.1058.33 ± 11.785
EF, CFB to Week 20811.90 ± 14.31912.50 ± 5.893
EF, CFB to Week 2110.00 ± 11.7858.33 ± 11.785
EF, CFB to Week 2140.00 ± 8.33312.50 ± 5.893
EF, CFB to Week 2170.00 ± 0.0004.17 ± 17.678
EF, CFB to Week 2204.17 ± 5.8938.33 ± 11.785
EF, CFB to Week 2234.17 ± 10.75812.50 ± 5.893
EF, CFB to Week 2265.56 ± 9.6230.00 ± NA
EF, CFB to Week 2298.33 ± 11.7858.33 ± NA
EF, CFB to Week 2320.00 ± 16.6678.33 ± NA
EF, CFB to Week 235-4.17 ± 5.8930.00 ± NA
EF, CFB to Week 238—8.33 ± NA
EF, CFB to EOT (~242 weeks)-5.53 ± 23.677-6.19 ± 21.098
EF, CFB to LFU (~263 weeks)-0.60 ± 20.32810.83 ± 26.366
CF, CFB to Week 40.75 ± 17.391-1.61 ± 16.175
CF, CFB to Week 70.68 ± 16.538-1.28 ± 20.766
CF, CFB to Week 10-0.13 ± 16.204-0.51 ± 22.042
CF, CFB to Week 13-0.75 ± 16.110-1.72 ± 21.332
CF, CFB to Week 16-4.09 ± 21.920-3.70 ± 19.870
CF, CFB to Week 19-1.55 ± 20.706-3.00 ± 18.347
CF, CFB to Week 22-1.91 ± 17.749-7.54 ± 20.889
CF, CFB to Week 25-1.99 ± 17.444-10.29 ± 25.955
CF, CFB to Week 28-2.55 ± 15.958-3.81 ± 17.191
CF, CFB to Week 31-0.64 ± 15.991-3.54 ± 14.882
CF, CFB to Week 34-2.05 ± 16.184-0.67 ± 14.814
CF, CFB to Week 37-1.45 ± 15.054-4.00 ± 12.981
CF, CFB to Week 40-1.67 ± 15.320-2.67 ± 12.435
CF, CFB to Week 43-0.48 ± 15.007-3.17 ± 22.123
CF, CFB to Week 46-0.26 ± 16.127-1.04 ± 14.232
CF, CFB to Week 492.60 ± 14.6140.88 ± 10.354
CF, CFB to Week 521.85 ± 15.0004.17 ± 13.107
CF, CFB to Week 553.06 ± 14.8732.63 ± 11.471
CF, CFB to Week 580.29 ± 18.4984.63 ± 15.971
CF, CFB to Week 611.31 ± 12.842-2.78 ± 17.386
CF, CFB to Week 640.00 ± 15.6350.00 ± 17.817
CF, CFB to Week 671.33 ± 14.9983.13 ± 16.351
CF, CFB to Week 70-0.67 ± 18.1205.13 ± 10.507
CF, CFB to Week 73-2.03 ± 13.5383.33 ± 12.910
CF, CFB to Week 76-0.79 ± 24.1251.11 ± 13.313
CF, CFB to Week 790.00 ± 17.2662.22 ± 15.258
CF, CFB to Week 823.49 ± 14.3464.44 ± 16.019
CF, CFB to Week 854.05 ± 16.3890.00 ± 18.002
CF, CFB to Week 88-1.39 ± 17.5372.56 ± 13.344
CF, CFB to Week 911.80 ± 17.909-3.57 ± 21.857
CF, CFB to Week 941.85 ± 15.8250.00 ± 7.107
CF, CFB to Week 97-1.67 ± 18.2313.03 ± 10.050
CF, CFB to Week 1001.90 ± 18.4231.67 ± 12.298
CF, CFB to Week 103-1.47 ± 18.5173.70 ± 11.111
CF, CFB to Week 106-4.55 ± 18.7612.38 ± 17.817
CF, CFB to Week 109-0.49 ± 15.067-2.08 ± 10.681
CF, CFB to Week 1120.56 ± 17.2230.00 ± 13.608
CF, CFB to Week 115-2.22 ± 17.9040.00 ± 12.599
CF, CFB to Week 118-2.78 ± 19.120-2.08 ± 13.909
CF, CFB to Week 121-2.00 ± 18.207-2.08 ± 10.681
CF, CFB to Week 124-5.13 ± 19.3042.78 ± 6.804
CF, CFB to Week 127-5.13 ± 15.470-5.56 ± 8.607
CF, CFB to Week 130-1.33 ± 15.899-6.67 ± 9.129
CF, CFB to Week 1330.00 ± 13.901-2.78 ± 6.804
CF, CFB to Week 136-2.38 ± 12.1173.33 ± 7.454
CF, CFB to Week 139-1.59 ± 11.6720.00 ± 0.000
CF, CFB to Week 142-2.27 ± 12.9050.00 ± 0.000
CF, CFB to Week 145-9.26 ± 16.3920.00 ± 0.000
CF, CFB to Week 148-3.51 ± 11.8880.00 ± 0.000
CF, CFB to Week 151-3.97 ± 15.7280.00 ± 0.000
CF, CFB to Week 154-1.75 ± 12.2910.00 ± 0.000
CF, CFB to Week 157-9.80 ± 16.7280.00 ± 0.000
CF, CFB to Week 160-11.11 ± 16.1695.56 ± 9.623
CF, CFB to Week 163-9.26 ± 15.3630.00 ± 0.000
CF, CFB to Week 166-6.67 ± 12.2805.56 ± 9.623
CF, CFB to Week 169-11.76 ± 18.413-5.56 ± 9.623
CF, CFB to Week 172-8.97 ± 17.5010.00 ± 0.000
CF, CFB to Week 1750.00 ± 7.1070.00 ± 0.000
CF, CFB to Week 178-1.19 ± 7.9115.56 ± 9.623
CF, CFB to Week 181-8.33 ± 14.248-5.56 ± 9.623
CF, CFB to Week 184-1.52 ± 5.025-5.56 ± 9.623
CF, CFB to Week 187-1.85 ± 13.0290.00 ± 0.000
CF, CFB to Week 1901.85 ± 15.4660.00 ± 0.000
CF, CFB to Week 1930.00 ± 9.6230.00 ± 0.000
CF, CFB to Week 1962.08 ± 10.6810.00 ± 16.667
CF, CFB to Week 199-11.90 ± 24.9340.00 ± 0.000
CF, CFB to Week 2021.85 ± 10.0150.00 ± 0.000
CF, CFB to Week 2050.00 ± 9.6238.33 ± 11.785
CF, CFB to Week 2084.76 ± 8.1330.00 ± 0.000
CF, CFB to Week 2113.33 ± 7.4548.33 ± 11.785
CF, CFB to Week 2140.00 ± 0.0008.33 ± 11.785
CF, CFB to Week 2170.00 ± 0.0008.33 ± 11.785
CF, CFB to Week 2208.33 ± 11.7858.33 ± 11.785
CF, CFB to Week 2234.17 ± 8.3338.33 ± 11.785
CF, CFB to Week 2260.00 ± 16.66716.67 ± NA
CF, CFB to Week 2298.33 ± 8.3316.67 ± NA
CF, CFB to Week 2325.56 ± 9.62316.67 ± NA
CF, CFB to Week 2350.00 ± 0.00016.67 ± NA
CF, CFB to Week 238—0.00 ± NA
CF, CFB to EOT (~242 weeks)-5.18 ± 21.452-7.58 ± 21.520
CF, CFB to LFU (~263 weeks)-5.31 ± 23.308-2.50 ± 21.134
SF, CFB to Week 41.99 ± 23.111-0.60 ± 21.376
SF, CFB to Week 7-0.46 ± 25.6670.00 ± 23.570
SF, CFB to Week 100.65 ± 23.608-0.26 ± 23.843
SF, CFB to Week 131.53 ± 25.614-1.72 ± 22.445
SF, CFB to Week 160.00 ± 26.069-0.64 ± 26.806
SF, CFB to Week 191.91 ± 27.346-1.00 ± 26.813
SF, CFB to Week 22-1.58 ± 29.180-4.37 ± 27.065
SF, CFB to Week 254.21 ± 28.284-2.45 ± 26.947
SF, CFB to Week 281.79 ± 29.6141.43 ± 26.926
SF, CFB to Week 314.11 ± 25.3852.53 ± 23.615
SF, CFB to Week 344.17 ± 26.940-0.67 ± 23.805
SF, CFB to Week 375.39 ± 28.425-1.33 ± 17.951
SF, CFB to Week 405.48 ± 27.762-2.67 ± 23.902
SF, CFB to Week 433.14 ± 26.7033.97 ± 24.667
SF, CFB to Week 464.50 ± 28.2732.08 ± 29.736
SF, CFB to Week 498.47 ± 23.1627.02 ± 26.244
SF, CFB to Week 5211.29 ± 23.5276.67 ± 25.015
SF, CFB to Week 553.39 ± 22.2707.02 ± 19.497
SF, CFB to Week 582.38 ± 29.0303.70 ± 25.918
SF, CFB to Week 615.00 ± 29.5957.41 ± 22.304
SF, CFB to Week 648.16 ± 28.2854.44 ± 27.070
SF, CFB to Week 674.42 ± 25.6347.29 ± 21.054
SF, CFB to Week 706.46 ± 27.3905.13 ± 21.926
SF, CFB to Week 73-0.41 ± 27.7614.44 ± 23.960
SF, CFB to Week 762.44 ± 27.2756.67 ± 22.537
SF, CFB to Week 796.91 ± 30.0418.89 ± 26.627
SF, CFB to Week 828.33 ± 28.80911.11 ± 17.442
SF, CFB to Week 859.26 ± 29.9323.85 ± 26.487
SF, CFB to Week 887.87 ± 30.46911.54 ± 25.806
SF, CFB to Week 9111.26 ± 27.7935.95 ± 31.082
SF, CFB to Week 947.41 ± 31.9835.56 ± 35.056
SF, CFB to Week 972.78 ± 28.05413.64 ± 27.707
SF, CFB to Week 1005.24 ± 27.04710.00 ± 36.175
SF, CFB to Week 1036.86 ± 26.3101.85 ± 25.610
SF, CFB to Week 1068.08 ± 30.9357.14 ± 31.706
SF, CFB to Week 10911.27 ± 28.9328.33 ± 28.172
SF, CFB to Week 11211.67 ± 28.4167.14 ± 33.134
SF, CFB to Week 1158.33 ± 25.8018.33 ± 30.861
SF, CFB to Week 1186.67 ± 32.6368.33 ± 28.172
SF, CFB to Week 1214.67 ± 27.85510.42 ± 25.099
SF, CFB to Week 1248.33 ± 27.18311.11 ± 41.722
SF, CFB to Week 1277.05 ± 33.05713.89 ± 30.581
SF, CFB to Week 1309.33 ± 30.0776.67 ± 25.276
SF, CFB to Week 1337.64 ± 37.74419.44 ± 30.581
SF, CFB to Week 1367.14 ± 29.14120.00 ± 21.731
SF, CFB to Week 1398.73 ± 28.19513.89 ± 30.581
SF, CFB to Week 14212.12 ± 26.81625.00 ± 31.914
SF, CFB to Week 1452.78 ± 34.41916.67 ± 23.570
SF, CFB to Week 1488.77 ± 29.06416.67 ± 33.333
SF, CFB to Week 1516.35 ± 35.93125.00 ± 21.517
SF, CFB to Week 154-1.75 ± 33.28520.83 ± 25.000
SF, CFB to Week 1573.92 ± 30.91722.22 ± 38.490
SF, CFB to Week 160-7.41 ± 30.90327.78 ± 25.459
SF, CFB to Week 163-1.85 ± 40.37827.78 ± 25.459
SF, CFB to Week 1662.22 ± 39.27216.67 ± 28.868
SF, CFB to Week 1691.96 ± 42.03327.78 ± 25.459
SF, CFB to Week 1728.97 ± 37.02816.67 ± 28.868
SF, CFB to Week 17512.50 ± 41.51527.78 ± 25.459
SF, CFB to Week 1781.19 ± 39.47516.67 ± 28.868
SF, CFB to Week 1817.14 ± 40.14627.78 ± 25.459
SF, CFB to Week 1841.52 ± 41.13327.78 ± 25.459
SF, CFB to Week 18711.11 ± 47.87141.67 ± 58.926
SF, CFB to Week 1909.26 ± 47.95238.89 ± 41.944
SF, CFB to Week 1939.52 ± 26.97227.78 ± 25.459
SF, CFB to Week 19627.08 ± 33.25938.89 ± 41.944
SF, CFB to Week 19911.90 ± 46.85927.78 ± 25.459
SF, CFB to Week 20212.96 ± 40.63527.78 ± 27.78
SF, CFB to Week 20526.19 ± 42.87916.67 ± 23.570
SF, CFB to Week 20821.43 ± 46.85916.67 ± 23.570
SF, CFB to Week 21110.00 ± 43.46116.67 ± 23.570
SF, CFB to Week 2140.00 ± 33.33316.67 ± 23.570
SF, CFB to Week 21716.67 ± 23.57016.67 ± 23.570
SF, CFB to Week 2200.00 ± 47.14016.67 ± 23.570
SF, CFB to Week 2238.33 ± 28.86816.67 ± 23.570
SF, CFB to Week 22616.67 ± 28.8680.00 ± NA
SF, CFB to Week 22933.33 ± 47.1400.00 ± NA
SF, CFB to Week 23216.67 ± 28.8680.00 ± NA
SF, CFB to Week 2350.00 ± 0.0000.00 ± NA
SF, CFB to Week 238—0.00 ± NA
SF, CFB to EOT (~242 weeks)-9.46 ± 29.995-6.57 ± 32.407
SF, CFB to LFU (~263 weeks)-3.92 ± 29.24110.00 ± 41.323
Fatigue, CFB to Week 4-3.66 ± 18.6910.95 ± 22.711
Fatigue, CFB to Week 7-3.91 ± 21.5870.00 ± 26.735
Fatigue, CFB to Week 10-4.82 ± 21.6840.53 ± 24.799
Fatigue, CFB to Week 13-7.51 ± 19.7534.09 ± 23.629
Fatigue, CFB to Week 16-5.77 ± 22.274-2.10 ± 22.335
Fatigue, CFB to Week 19-7.06 ± 19.5052.27 ± 23.238
Fatigue, CFB to Week 22-5.61 ± 19.1170.00 ± 21.373
Fatigue, CFB to Week 25-5.37 ± 22.0303.70 ± 24.637
Fatigue, CFB to Week 28-6.02 ± 21.529-0.98 ± 22.451
Fatigue, CFB to Week 31-3.97 ± 19.179-0.35 ± 21.583
Fatigue, CFB to Week 34-4.03 ± 21.936-2.31 ± 20.456
Fatigue, CFB to Week 37-5.96 ± 20.4363.24 ± 16.860
Fatigue, CFB to Week 40-8.97 ± 20.3584.63 ± 22.443
Fatigue, CFB to Week 43-8.65 ± 21.2681.11 ± 15.672
Fatigue, CFB to Week 46-10.07 ± 24.704-4.17 ± 21.033
Fatigue, CFB to Week 49-9.64 ± 21.419-2.92 ± 21.225
Fatigue, CFB to Week 52-10.22 ± 23.228-5.00 ± 17.090
Fatigue, CFB to Week 55-10.19 ± 19.9700.58 ± 17.163
Fatigue, CFB to Week 58-7.41 ± 23.4140.62 ± 19.975
Fatigue, CFB to Week 61-11.78 ± 22.7171.85 ± 27.016
Fatigue, CFB to Week 64-13.29 ± 22.773-0.74 ± 17.042
Fatigue, CFB to Week 67-9.22 ± 22.040-2.78 ± 22.407
Fatigue, CFB to Week 70-12.00 ± 24.4710.85 ± 16.013
Fatigue, CFB to Week 73-6.11 ± 25.8993.70 ± 24.727
Fatigue, CFB to Week 76-7.41 ± 23.623-2.96 ± 26.047
Fatigue, CFB to Week 79-13.76 ± 18.659-6.67 ± 22.537
Fatigue, CFB to Week 82-11.11 ± 25.738-2.96 ± 18.999
Fatigue, CFB to Week 85-14.11 ± 23.226-2.56 ± 21.827
Fatigue, CFB to Week 88-10.19 ± 25.528-2.56 ± 19.852
Fatigue, CFB to Week 91-9.61 ± 27.363-0.79 ± 26.675
Fatigue, CFB to Week 94-12.96 ± 22.9257.41 ± 34.274
Fatigue, CFB to Week 97-12.78 ± 27.105-2.02 ± 21.556
Fatigue, CFB to Week 100-12.38 ± 25.8161.11 ± 28.903
Fatigue, CFB to Week 103-12.75 ± 23.7100.00 ± 29.918
Fatigue, CFB to Week 106-13.47 ± 24.6523.17 ± 30.574
Fatigue, CFB to Week 109-12.75 ± 23.2320.00 ± 38.029
Fatigue, CFB to Week 112-15.08 ± 26.573-4.76 ± 26.338
Fatigue, CFB to Week 115-8.89 ± 26.6480.00 ± 19.698
Fatigue, CFB to Week 118-11.11 ± 27.373-1.39 ± 25.502
Fatigue, CFB to Week 121-12.89 ± 23.058-5.56 ± 23.002
Fatigue, CFB to Week 124-8.55 ± 30.519-9.26 ± 29.327
Fatigue, CFB to Week 127-6.84 ± 26.865-7.41 ± 24.003
Fatigue, CFB to Week 130-13.78 ± 26.309-6.67 ± 28.974
Fatigue, CFB to Week 133-12.96 ± 25.520-7.41 ± 30.361
Fatigue, CFB to Week 136-15.87 ± 27.119-8.89 ± 33.702
Fatigue, CFB to Week 139-8.99 ± 23.206-7.41 ± 30.361
Fatigue, CFB to Week 142-9.09 ± 23.666-11.11 ± 38.490
Fatigue, CFB to Week 145-3.70 ± 22.222-8.89 ± 33.702
Fatigue, CFB to Week 148-6.14 ± 23.196-16.67 ± 33.333
Fatigue, CFB to Week 151-3.17 ± 21.700-13.89 ± 35.573
Fatigue, CFB to Week 154-11.11 ± 26.189-11.11 ± 38.490
Fatigue, CFB to Week 157-5.23 ± 23.609-11.11 ± 50.918
Fatigue, CFB to Week 160-3.09 ± 23.741-14.81 ± 46.259
Fatigue, CFB to Week 163-6.79 ± 26.986-14.81 ± 35.717
Fatigue, CFB to Week 166-8.15 ± 25.010-14.81 ± 46.259
Fatigue, CFB to Week 169-7.84 ± 26.283-14.81 ± 35.717
Fatigue, CFB to Week 172-10.26 ± 27.764-11.11 ± 40.062
Fatigue, CFB to Week 175-14.81 ± 27.354-18.52 ± 42.066
Fatigue, CFB to Week 178-8.73 ± 27.279-18.52 ± 32.075
Fatigue, CFB to Week 181-6.35 ± 26.045-7.41 ± 44.905
Fatigue, CFB to Week 184-7.07 ± 24.481-18.52 ± 42.066
Fatigue, CFB to Week 187-6.17 ± 29.975-22.22 ± 62.854
Fatigue, CFB to Week 190-7.78 ± 28.713-14.81 ± 46.259
Fatigue, CFB to Week 193-1.59 ± 26.001-18.52 ± 42.066
Fatigue, CFB to Week 196-15.28 ± 32.496-18.52 ± 42.066
Fatigue, CFB to Week 199-1.59 ± 33.597-11.11 ± 40.062
Fatigue, CFB to Week 202-14.81 ± 30.429-18.52 ± 42.066
Fatigue, CFB to Week 205-12.70 ± 36.53116.67 ± 23.570
Fatigue, CFB to Week 208-9.52 ± 35.96311.11 ± 15.713
Fatigue, CFB to Week 211-8.89 ± 32.77311.11 ± 15.713
Fatigue, CFB to Week 214-3.70 ± 39.02111.11 ± 15.713
Fatigue, CFB to Week 2170.00 ± 0.00011.11 ± 15.713
Fatigue, CFB to Week 22011.11 ± 31.42716.67 ± 23.570
Fatigue, CFB to Week 2232.78 ± 22.9065.56 ± 7.857
Fatigue, CFB to Week 226-3.70 ± 16.97322.22 ± NA
Fatigue, CFB to Week 2290.00 ± 31.4270.00 ± NA
Fatigue, CFB to Week 232-3.70 ± 16.97311.11 ± NA
Fatigue, CFB to Week 2350.00 ± 0.00022.22 ± NA
Fatigue, CFB to Week 238—0.00 ± NA
Fatigue, CFB to EOT (~242 weeks)1.77 ± 27.3017.12 ± 26.440
Fatigue, CFB to LFU (~263 weeks)0.25 ± 28.835-6.11 ± 30.263
N/V, CFB to Week 43.52 ± 17.470-0.20 ± 10.309
N/V, CFB to Week 71.49 ± 16.8872.35 ± 16.055
N/V, CFB to Week 10-0.79 ± 14.677-0.78 ± 8.622
N/V, CFB to Week 13-1.83 ± 17.1741.15 ± 15.877
N/V, CFB to Week 16-1.92 ± 15.633-0.93 ± 13.118
N/V, CFB to Week 19-2.51 ± 14.5270.33 ± 11.414
N/V, CFB to Week 22-1.25 ± 20.1502.44 ± 13.724
N/V, CFB to Week 25-2.75 ± 15.3692.45 ± 13.061
N/V, CFB to Week 28-0.60 ± 13.8820.95 ± 12.088
N/V, CFB to Week 31-1.08 ± 14.3930.51 ± 12.137
N/V, CFB to Week 341.85 ± 15.462-1.33 ± 10.672
N/V, CFB to Week 37-0.98 ± 11.8321.33 ± 10.672
N/V, CFB to Week 40-1.67 ± 13.0500.00 ± 8.333
N/V, CFB to Week 43-0.48 ± 14.844-1.59 ± 11.672
N/V, CFB to Week 46-2.65 ± 11.673-1.04 ± 9.562
N/V, CFB to Week 49-2.38 ± 10.733-0.93 ± 8.988
N/V, CFB to Week 52-2.19 ± 12.351-1.67 ± 7.454
N/V, CFB to Week 55-1.72 ± 11.121-1.75 ± 7.647
N/V, CFB to Week 580.30 ± 13.292-0.93 ± 8.988
N/V, CFB to Week 61-3.67 ± 13.1660.00 ± 11.433
N/V, CFB to Week 64-3.74 ± 11.915-1.11 ± 16.019
N/V, CFB to Week 67-3.82 ± 13.4220.00 ± 10.541
N/V, CFB to Week 70-4.08 ± 12.043-3.85 ± 13.868
N/V, CFB to Week 73-3.25 ± 10.685-2.22 ± 13.897
N/V, CFB to Week 76-3.66 ± 7.916-1.11 ± 9.894
N/V, CFB to Week 79-3.25 ± 10.685-1.11 ± 9.894
N/V, CFB to Week 82-3.57 ± 12.502-2.22 ± 13.897
N/V, CFB to Week 85-4.17 ± 12.199-3.85 ± 13.868
N/V, CFB to Week 88-1.85 ± 15.825-3.85 ± 13.868
N/V, CFB to Week 91-3.24 ± 11.832-2.38 ± 14.407
N/V, CFB to Week 94-4.17 ± 10.059-1.39 ± 11.143
N/V, CFB to Week 97-1.11 ± 11.525-1.52 ± 11.677
N/V, CFB to Week 100-1.43 ± 10.203-1.67 ± 12.298
N/V, CFB to Week 103-2.45 ± 10.958-4.17 ± 11.785
N/V, CFB to Week 106-2.02 ± 13.015-4.76 ± 20.893
N/V, CFB to Week 109-3.92 ± 9.229-2.08 ± 22.603
N/V, CFB to Week 112-4.60 ± 9.857-2.38 ± 14.996
N/V, CFB to Week 115-2.22 ± 11.3570.00 ± 17.817
N/V, CFB to Week 118-3.33 ± 10.171-4.17 ± 11.785
N/V, CFB to Week 121-3.47 ± 12.984-6.25 ± 17.678
N/V, CFB to Week 124-1.28 ± 11.473-8.33 ± 20.412
N/V, CFB to Week 127-0.64 ± 12.893-8.33 ± 20.412
N/V, CFB to Week 130-0.67 ± 13.159-6.67 ± 14.907
N/V, CFB to Week 133-1.39 ± 13.8280.00 ± 0.000
N/V, CFB to Week 136-3.97 ± 8.9830.00 ± 0.000
N/V, CFB to Week 139-4.76 ± 9.3440.00 ± 0.000
N/V, CFB to Week 142-1.52 ± 8.7730.00 ± 0.000
N/V, CFB to Week 1450.00 ± 9.9010.00 ± 0.000
N/V, CFB to Week 148-2.63 ± 10.0360.00 ± 0.000
N/V, CFB to Week 151-3.97 ± 8.9830.00 ± 0.000
N/V, CFB to Week 154-4.39 ± 10.8900.00 ± 0.000
N/V, CFB to Week 157-4.90 ± 12.8620.00 ± 0.000
N/V, CFB to Week 160-3.70 ± 12.2018.33 ± 11.785
N/V, CFB to Week 163-6.48 ± 11.6300.00 ± 0.000
N/V, CFB to Week 166-5.56 ± 12.0620.00 ± 0.000
N/V, CFB to Week 169-5.88 ± 11.6980.00 ± 0.000
N/V, CFB to Week 172-7.69 ± 12.9380.00 ± 0.000
N/V, CFB to Week 175-4.17 ± 10.3600.00 ± 0.000
N/V, CFB to Week 178-2.38 ± 11.0500.00 ± 0.000
N/V, CFB to Week 181-1.19 ± 13.8120.00 ± 0.000
N/V, CFB to Week 1840.00 ± 12.9100.00 ± 0.000
N/V, CFB to Week 187-3.70 ± 11.1110.00 ± 0.000
N/V, CFB to Week 190-8.33 ± 14.1640.00 ± 0.000
N/V, CFB to Week 193-4.76 ± 12.5990.00 ± 0.000
N/V, CFB to Week 196-6.25 ± 12.4000.00 ± 0.000
N/V, CFB to Week 1990.00 ± 0.0000.00 ± 0.000
N/V, CFB to Week 202-5.56 ± 11.7850.00 ± 0.000
N/V, CFB to Week 205-7.14 ± 13.1130.00 ± 0.000
N/V, CFB to Week 208-7.14 ± 13.1130.00 ± 0.000
N/V, CFB to Week 211-10.00 ± 14.9070.00 ± 0.000
N/V, CFB to Week 214-5.56 ± 9.6230.00 ± 0.000
N/V, CFB to Week 2170.00 ± 0.0000.00 ± 0.000
N/V, CFB to Week 220-16.67 ± 23.5700.00 ± 0.000
N/V, CFB to Week 223-8.33 ± 16.6670.00 ± 0.000
N/V, CFB to Week 226-11.11 ± 19.2450.00 ± NA
N/V, CFB to Week 229-16.67 ± 23.5700.00 ± NA
N/V, CFB to Week 232-11.11 ± 19.2450.00 ± NA
N/V, CFB to Week 2350.00 ± 0.0000.00 ± NA
N/V, CFB to Week 238—0.00 ± NA
N/V, CFB to EOT (~242 weeks)1.99 ± 23.5873.08 ± 12.109
N/V, CFB to LFU (~263 weeks)1.93 ± 19.0756.67 ± 21.898
Pain, CFB to Week 4-1.51 ± 23.589-1.41 ± 26.571
Pain, CFB to Week 7-3.17 ± 24.546-4.27 ± 30.441
Pain, CFB to Week 10-2.31 ± 24.445-6.41 ± 30.146
Pain, CFB to Week 13-5.56 ± 24.856-8.05 ± 22.780
Pain, CFB to Week 16-6.29 ± 27.454-7.41 ± 31.667
Pain, CFB to Week 19-6.36 ± 29.012-2.67 ± 27.013
Pain, CFB to Week 22-4.34 ± 29.044-4.37 ± 30.144
Pain, CFB to Week 25-7.97 ± 25.616-5.88 ± 26.869
Pain, CFB to Week 28-4.96 ± 24.514-6.19 ± 24.617
Pain, CFB to Week 31-6.62 ± 24.374-7.58 ± 21.687
Pain, CFB to Week 34-3.88 ± 24.771-6.00 ± 21.452
Pain, CFB to Week 37-8.70 ± 25.6630.67 ± 17.665
Pain, CFB to Week 40-7.86 ± 25.494-1.33 ± 11.706
Pain, CFB to Week 43-7.86 ± 27.3230.00 ± 21.082
Pain, CFB to Week 46-7.29 ± 27.5190.00 ± 16.102
Pain, CFB to Week 49-6.51 ± 26.4970.00 ± 13.608
Pain, CFB to Week 52-10.32 ± 26.846-4.17 ± 13.107
Pain, CFB to Week 55-3.89 ± 28.8460.88 ± 20.393
Pain, CFB to Week 58-9.65 ± 29.370-1.85 ± 17.977
Pain, CFB to Week 61-9.67 ± 25.2182.78 ± 21.580
Pain, CFB to Week 64-10.13 ± 28.300-2.22 ± 12.387
Pain, CFB to Week 67-12.00 ± 26.735-8.33 ± 17.213
Pain, CFB to Week 70-12.00 ± 26.522-5.13 ± 18.490
Pain, CFB to Week 73-10.16 ± 24.4034.44 ± 14.729
Pain, CFB to Week 7615-8.33 ± 25.833-3.33 ± 22.003
Pain, CFB to Week 79-9.52 ± 27.826-3.33 ± 18.039
Pain, CFB to Week 82-10.47 ± 29.327-8.89 ± 18.758
Pain, CFB to Week 85-12.16 ± 31.829-2.56 ± 19.059
Pain, CFB to Week 88-12.96 ± 29.307-1.28 ± 25.875
Pain, CFB to Week 91-11.71 ± 31.6391.19 ± 33.630
Pain, CFB to Week 94-11.11 ± 30.0796.94 ± 35.146
Pain, CFB to Week 97-10.56 ± 24.559-6.06 ± 15.407
Pain, CFB to Week 100-11.90 ± 27.288-1.67 ± 41.907
Pain, CFB to Week 103-10.78 ± 26.235-5.56 ± 31.180
Pain, CFB to Week 106-12.12 ± 27.724-7.14 ± 26.972
Pain, CFB to Week 109-12.75 ± 29.3194.17 ± 37.533
Pain, CFB to Week 112-13.33 ± 30.1340.00 ± 34.694
Pain, CFB to Week 115-8.89 ± 29.2740.00 ± 19.920
Pain, CFB to Week 118-9.44 ± 24.6372.08 ± 32.657
Pain, CFB to Week 121-10.00 ± 27.639-4.17 ± 19.416
Pain, CFB to Week 124-12.82 ± 29.555-11.11 ± 29.187
Pain, CFB to Week 127-12.82 ± 26.795-11.11 ± 27.217
Pain, CFB to Week 130-14.00 ± 23.902-6.67 ± 25.276
Pain, CFB to Week 133-11.81 ± 29.684-8.33 ± 22.973
Pain, CFB to Week 136-11.11 ± 25.999-13.33 ± 29.814
Pain, CFB to Week 139-9.52 ± 25.588-5.56 ± 34.427
Pain, CFB to Week 142-12.12 ± 31.782-12.50 ± 36.956
Pain, CFB to Week 145-3.70 ± 25.918-10.00 ± 22.361
Pain, CFB to Week 148-14.04 ± 29.008-8.33 ± 28.868
Pain, CFB to Week 151-8.73 ± 25.614-8.33 ± 28.868
Pain, CFB to Week 154-8.77 ± 27.425-4.17 ± 8.333
Pain, CFB to Week 157-2.94 ± 30.182-16.67 ± 44.096
Pain, CFB to Week 160-4.63 ± 25.441-16.67 ± 44.096
Pain, CFB to Week 163-10.19 ± 30.324-16.67 ± 44.096
Pain, CFB to Week 166-12.22 ± 27.070-16.67 ± 44.096
Pain, CFB to Week 169-7.84 ± 24.380-22.22 ± 38.490
Pain, CFB to Week 172-11.54 ± 32.192-16.67 ± 28.868
Pain, CFB to Week 175-16.67 ± 27.524-16.67 ± 44.096
Pain, CFB to Week 178-7.14 ± 33.150-33.33 ± 33.333
Pain, CFB to Week 181-2.38 ± 40.222-5.56 ± 41.944
Pain, CFB to Week 184-3.03 ± 35.604-22.22 ± 38.490
Pain, CFB to Week 1870.00 ± 44.876-25.00 ± 58.926
Pain, CFB to Week 190-8.33 ± 41.759-11.11 ± 50.918
Pain, CFB to Week 193-7.14 ± 30.211-5.56 ± 41.944
Pain, CFB to Week 196-22.92 ± 29.463-16.67 ± 44.096
Pain, CFB to Week 199-7.14 ± 30.211-16.67 ± 44.096
Pain, CFB to Week 202-18.52 ± 34.805-16.67 ± 44.096
Pain, CFB to Week 205-19.05 ± 36.55116.67 ± 23.570
Pain, CFB to Week 208-16.67 ± 34.69416.67 ± 23.570
Pain, CFB to Week 211-16.67 ± 40.8258.33 ± 11.785
Pain, CFB to Week 214-11.11 ± 34.6940.00 ± 0.000
Pain, CFB to Week 2170.00 ± 0.0008.33 ± 11.785
Pain, CFB to Week 2200.00 ± 47.14016.67 ± 23.570
Pain, CFB to Week 223-4.17 ± 34.3590.00 ± 0.000
Pain, CFB to Week 226-11.11 ± 19.2450.00 ± NA
Pain, CFB to Week 229-33.33 ± 47.140-16.67 ± NA
Pain, CFB to Week 232-5.56 ± 41.9440.00 ± NA
Pain, CFB to Week 2350.00 ± 0.00016.67 ± NA
Pain, CFB to Week 238—0.00 ± NA
Pain, CFB to EOT (~242 weeks)4.24 ± 30.0513.28 ± 27.303
Pain, CFB to LFU (~263 weeks)1.21 ± 32.252-10.00 ± 29.814
Dyspnea, CFB to Week 41.13 ± 23.8104.82 ± 24.491
Dyspnea, CFB to Week 70.46 ± 21.7922.16 ± 25.557
Dyspnea, CFB to Week 102.07 ± 23.4796.15 ± 27.571
Dyspnea, CFB to Week 13-1.52 ± 24.0576.90 ± 26.312
Dyspnea, CFB to Week 16-4.44 ± 26.1769.26 ± 24.586
Dyspnea, CFB to Week 19-3.13 ± 23.7328.67 ± 26.777
Dyspnea, CFB to Week 22-2.13 ± 24.3477.94 ± 24.205
Dyspnea, CFB to Week 25-2.22 ± 23.33111.46 ± 26.246
Dyspnea, CFB to Week 280.00 ± 23.2816.67 ± 26.568
Dyspnea, CFB to Week 31-0.43 ± 21.2846.06 ± 25.624
Dyspnea, CFB to Week 340.93 ± 20.1505.33 ± 22.933
Dyspnea, CFB to Week 37-3.92 ± 23.4158.00 ± 19.907
Dyspnea, CFB to Week 40-1.45 ± 25.2029.33 ± 20.458
Dyspnea, CFB to Week 430.48 ± 23.9097.94 ± 27.698
Dyspnea, CFB to Week 46-4.76 ± 25.9982.08 ± 25.730
Dyspnea, CFB to Week 49-1.59 ± 25.7011.75 ± 25.995
Dyspnea, CFB to Week 52-1.64 ± 26.1248.33 ± 30.349
Dyspnea, CFB to Week 55-1.15 ± 25.7183.51 ± 15.294
Dyspnea, CFB to Week 582.38 ± 25.3129.26 ± 27.548
Dyspnea, CFB to Week 61-6.00 ± 22.0189.26 ± 19.150
Dyspnea, CFB to Week 64-0.67 ± 23.8008.89 ± 19.787
Dyspnea, CFB to Week 67-3.40 ± 24.7638.33 ± 19.245
Dyspnea, CFB to Week 70-1.36 ± 27.1827.69 ± 24.167
Dyspnea, CFB to Week 73-3.33 ± 29.0408.89 ± 23.458
Dyspnea, CFB to Week 761.63 ± 25.7678.89 ± 23.458
Dyspnea, CFB to Week 79-1.63 ± 22.30011.11 ± 32.530
Dyspnea, CFB to Week 82-4.88 ± 20.4958.89 ± 32.038
Dyspnea, CFB to Week 85-5.41 ± 22.9245.13 ± 18.490
Dyspnea, CFB to Week 88-2.78 ± 24.3987.69 ± 19.971
Dyspnea, CFB to Week 910.00 ± 23.57011.90 ± 28.063
Dyspnea, CFB to Week 94-3.70 ± 19.1535.56 ± 23.925
Dyspnea, CFB to Week 97-2.22 ± 21.3236.06 ± 20.101
Dyspnea, CFB to Week 100-0.95 ± 24.8996.67 ± 14.055
Dyspnea, CFB to Week 103-1.96 ± 21.62011.11 ± 16.667
Dyspnea, CFB to Week 106-2.02 ± 24.9169.52 ± 25.198
Dyspnea, CFB to Week 109-5.88 ± 22.4298.33 ± 15.430
Dyspnea, CFB to Week 112-1.15 ± 30.188-4.76 ± 12.599
Dyspnea, CFB to Week 115-1.11 ± 23.9474.17 ± 21.362
Dyspnea, CFB to Week 118-2.22 ± 23.0508.33 ± 23.570
Dyspnea, CFB to Week 121-4.00 ± 29.3764.17 ± 11.785
Dyspnea, CFB to Week 124-8.97 ± 22.2265.56 ± 13.608
Dyspnea, CFB to Week 127-5.13 ± 20.42311.11 ± 17.213
Dyspnea, CFB to Week 130-9.33 ± 22.6080.00 ± 27.217
Dyspnea, CFB to Week 133-12.50 ± 25.65611.11 ± 17.213
Dyspnea, CFB to Week 136-9.52 ± 26.1250.00 ± 0.000
Dyspnea, CFB to Week 139-6.35 ± 20.0535.56 ± 13.608
Dyspnea, CFB to Week 142-13.64 ± 19.6780.00 ± 0.000
Dyspnea, CFB to Week 145-5.56 ± 26.1970.00 ± 0.000
Dyspnea, CFB to Week 148-8.77 ± 21.7798.33 ± 16.667
Dyspnea, CFB to Week 151-9.52 ± 23.9050.00 ± 0.000
Dyspnea, CFB to Week 154-7.02 ± 21.0200.00 ± 0.000
Dyspnea, CFB to Week 157-5.88 ± 13.0980.00 ± 0.000
Dyspnea, CFB to Week 160-5.56 ± 17.1500.00 ± 0.000
Dyspnea, CFB to Week 163-11.11 ± 19.8030.00 ± 0.000
Dyspnea, CFB to Week 166-4.44 ± 17.2130.00 ± 0.000
Dyspnea, CFB to Week 169-7.84 ± 22.140-11.11 ± 19.245
Dyspnea, CFB to Week 172-10.26 ± 25.0360.00 ± 0.000
Dyspnea, CFB to Week 175-11.11 ± 25.950-11.11 ± 19.245
Dyspnea, CFB to Week 178-4.76 ± 22.1000.00 ± 0.000
Dyspnea, CFB to Week 181-11.90 ± 21.1110.00 ± 0.000
Dyspnea, CFB to Week 184-9.09 ± 21.5560.00 ± 0.000
Dyspnea, CFB to Week 187-14.81 ± 24.2160.00 ± 0.000
Dyspnea, CFB to Week 190-6.67 ± 26.2940.00 ± 0.000
Dyspnea, CFB to Week 193-9.52 ± 16.2650.00 ± 0.000
Dyspnea, CFB to Week 196-12.50 ± 24.801-11.11 ± 19.245
Dyspnea, CFB to Week 199-9.52 ± 25.1980.00 ± 0.000
Dyspnea, CFB to Week 202-11.11 ± 23.5700.00 ± 0.000
Dyspnea, CFB to Week 205-14.29 ± 26.2270.00 ± 0.000
Dyspnea, CFB to Week 208-19.05 ± 26.2270.00 ± 0.000
Dyspnea, CFB to Week 211-6.67 ± 14.9070.00 ± 0.000
Dyspnea, CFB to Week 214-11.11 ± 19.2450.00 ± 0.000
Dyspnea, CFB to Week 2170.00 ± 0.0000.00 ± 0.000
Dyspnea, CFB to Week 220-16.67 ± 23.5700.00 ± 0.000
Dyspnea, CFB to Week 223-8.33 ± 16.6670.00 ± 0.00
Dyspnea, CFB to Week 226-11.11 ± 19.2450.00 ± NA
Dyspnea, CFB to Week 229-16.67 ± 23.570-33.33 ± NA
Dyspnea, CFB to Week 232-11.11 ± 19.2450.00 ± NA
Dyspnea, CFB to Week 2350.00 ± 0.0000.00 ± NA
Dyspnea, CFB to Week 238—0.00 ± NA
Dyspnea, CFB to EOT (~242 weeks)0.00 ± 24.5499.60 ± 21.693
Dyspnea, CFB to LFU (~263 weeks)1.96 ± 35.9118.33 ± 33.985
Insomnia, CFB to Week 4-2.12 ± 27.644-2.44 ± 29.528
Insomnia, CFB to Week 7-2.55 ± 26.760-3.03 ± 32.973
Insomnia, CFB to Week 10-6.25 ± 26.373-1.59 ± 29.590
Insomnia, CFB to Week 13-2.80 ± 28.270-4.68 ± 27.774
Insomnia, CFB to Week 16-2.86 ± 32.395-4.40 ± 26.983
Insomnia, CFB to Week 19-10.53 ± 30.466-5.44 ± 30.692
Insomnia, CFB to Week 22-7.09 ± 26.717-0.81 ± 31.170
Insomnia, CFB to Week 25-9.06 ± 28.4324.04 ± 40.618
Insomnia, CFB to Week 28-5.95 ± 24.9022.94 ± 27.668
Insomnia, CFB to Week 31-5.19 ± 27.072-5.21 ± 26.920
Insomnia, CFB to Week 34-3.65 ± 30.713-4.17 ± 29.996
Insomnia, CFB to Week 37-4.90 ± 25.925-4.17 ± 29.996
Insomnia, CFB to Week 40-5.24 ± 28.734-2.78 ± 33.932
Insomnia, CFB to Week 43-8.57 ± 32.9381.67 ± 36.635
Insomnia, CFB to Week 46-9.38 ± 26.206-6.25 ± 34.894
Insomnia, CFB to Week 49-8.85 ± 26.721-1.75 ± 30.376
Insomnia, CFB to Week 52-9.14 ± 28.419-5.00 ± 27.091
Insomnia, CFB to Week 55-8.89 ± 24.446-3.51 ± 24.582
Insomnia, CFB to Week 58-7.74 ± 33.6300.00 ± 32.338
Insomnia, CFB to Week 61-12.00 ± 24.981-3.70 ± 22.547
Insomnia, CFB to Week 64-10.46 ± 24.486-8.89 ± 23.458
Insomnia, CFB to Week 67-7.33 ± 27.180-2.08 ± 35.421
Insomnia, CFB to Week 70-10.00 ± 26.298-7.69 ± 30.894
Insomnia, CFB to Week 73-4.17 ± 26.352-4.44 ± 30.516
Insomnia, CFB to Week 76-6.35 ± 25.7550.00 ± 33.333
Insomnia, CFB to Week 79-7.14 ± 27.086-6.67 ± 31.371
Insomnia, CFB to Week 82-10.32 ± 27.038-2.22 ± 26.627
Insomnia, CFB to Week 85-12.61 ± 31.770-10.26 ± 36.980
Insomnia, CFB to Week 88-7.41 ± 26.561-2.56 ± 31.802
Insomnia, CFB to Week 91-2.70 ± 31.796-11.90 ± 33.607
Insomnia, CFB to Week 94-11.11 ± 30.861-11.11 ± 21.711
Insomnia, CFB to Week 97-13.33 ± 32.2823.03 ± 34.816
Insomnia, CFB to Week 100-8.57 ± 31.667-10.00 ± 27.442
Insomnia, CFB to Week 103-17.65 ± 29.854-11.11 ± 28.868
Insomnia, CFB to Week 106-13.13 ± 28.795-14.29 ± 26.227
Insomnia, CFB to Week 109-13.73 ± 27.362-16.67 ± 25.198
Insomnia, CFB to Week 112-14.29 ± 29.297-14.29 ± 17.817
Insomnia, CFB to Week 115-6.67 ± 28.2300.00 ± 25.198
Insomnia, CFB to Week 118-8.89 ± 32.676-12.50 ± 24.801
Insomnia, CFB to Week 121-10.67 ± 28.415-4.17 ± 21.362
Insomnia, CFB to Week 124-2.56 ± 32.555-5.56 ± 25.092
Insomnia, CFB to Week 127-7.69 ± 23.679-11.11 ± 17.213
Insomnia, CFB to Week 1300.00 ± 30.429-6.67 ± 14.907
Insomnia, CFB to Week 133-6.94 ± 25.9685.56 ± 25.092
Insomnia, CFB to Week 136-3.17 ± 25.6140.00 ± 23.570
Insomnia, CFB to Week 139-4.76 ± 30.342-5.56 ± 13.608
Insomnia, CFB to Week 142-3.03 ± 27.039-8.33 ± 16.667
Insomnia, CFB to Week 145-3.70 ± 32.1136.67 ± 14.907
Insomnia, CFB to Week 148-5.26 ± 22.942-8.33 ± 16.667
Insomnia, CFB to Week 151-3.17 ± 23.3450.00 ± 27.217
Insomnia, CFB to Week 154-5.26 ± 27.807-8.33 ± 16.667
Insomnia, CFB to Week 157-1.96 ± 29.9780.00 ± 33.333
Insomnia, CFB to Week 1601.85 ± 26.746-11.11 ± 19.245
Insomnia, CFB to Week 163-3.70 ± 27.7450.00 ± 0.000
Insomnia, CFB to Week 166-2.22 ± 23.458-11.11 ± 19.245
Insomnia, CFB to Week 169-7.84 ± 27.712-11.11 ± 19.245
Insomnia, CFB to Week 172-10.26 ± 34.385-11.11 ± 19.245
Insomnia, CFB to Week 175-11.11 ± 29.588-11.11 ± 19.245
Insomnia, CFB to Week 178-4.76 ± 34.237-11.11 ± 19.245
Insomnia, CFB to Week 181-4.76 ± 36.6480.00 ± 33.333
Insomnia, CFB to Week 184-9.09 ± 30.1510.00 ± 33.333
Insomnia, CFB to Week 18711.11 ± 47.1400.00 ± 47.140
Insomnia, CFB to Week 190-3.33 ± 50.7960.00 ± 33.333
Insomnia, CFB to Week 193-19.05 ± 26.227-11.11 ± 19.245
Insomnia, CFB to Week 196-20.83 ± 30.538-11.11 ± 19.245
Insomnia, CFB to Week 199-4.76 ± 23.002-11.11 ± 19.245
Insomnia, CFB to Week 202-3.70 ± 38.889-11.11 ± 19.245
Insomnia, CFB to Week 205-14.29 ± 42.41416.67 ± 23.570
Insomnia, CFB to Week 208-19.05 ± 32.5300.00 ± 0.000
Insomnia, CFB to Week 211-26.67 ± 27.8890.00 ± 0.000
Insomnia, CFB to Week 214-22.22 ± 19.2450.00 ± 0.000
Insomnia, CFB to Week 2170.00 ± 0.0000.00 ± 0.000
Insomnia, CFB to Week 220-50.00 ± 23.57016.67 ± 23.570
Insomnia, CFB to Week 223-25.00 ± 31.91416.67 ± 23.570
Insomnia, CFB to Week 226-22.22 ± 38.49033.33 ± NA
Insomnia, CFB to Week 229-33.33 ± 47.1400.00 ± NA
Insomnia, CFB to Week 232-22.22 ± 38.49033.33 ± NA
Insomnia, CFB to Week 2350.00 ± 0.0000.00 ± NA
Insomnia, CFB to Week 238—0.00 ± NA
Insomnia, CFB to EOT (~242 weeks)-2.56 ± 30.6861.04 ± 34.615
Insomnia, CFB to LFU (~263 weeks)-2.42 ± 28.191-16.67 ± 25.363
AL, CFB to Week 41.71 ± 24.5701.23 ± 22.635
AL, CFB to Week 7-2.55 ± 26.760-0.43 ± 24.320
AL, CFB to Week 10-1.85 ± 25.7532.08 ± 28.406
AL, CFB to Week 13-1.83 ± 29.3390.57 ± 22.934
AL, CFB to Week 16-2.56 ± 29.992-3.09 ± 21.736
AL, CFB to Week 19-4.71 ± 31.480-2.67 ± 21.125
AL, CFB to Week 22-1.08 ± 30.0770.81 ± 17.461
AL, CFB to Week 25-1.83 ± 28.7013.92 ± 15.922
AL, CFB to Week 28-2.81 ± 22.2120.95 ± 18.935
AL, CFB to Week 31-2.16 ± 22.5163.03 ± 15.284
AL, CFB to Week 341.39 ± 26.5004.00 ± 11.055
AL, CFB to Week 37-3.43 ± 28.2966.67 ± 13.608
AL, CFB to Week 40-4.29 ± 25.9589.33 ± 20.458
AL, CFB to Week 43-4.83 ± 26.3683.17 ± 10.026
AL, CFB to Week 46-5.82 ± 26.4644.17 ± 11.386
AL, CFB to Week 49-4.76 ± 27.3425.56 ± 12.783
AL, CFB to Week 52-7.65 ± 25.3813.33 ± 10.260
AL, CFB to Week 55-9.77 ± 22.5203.51 ± 10.510
AL, CFB to Week 58-5.95 ± 27.7857.41 ± 18.277
AL, CFB to Week 61-8.00 ± 24.7993.70 ± 10.779
AL, CFB to Week 64-8.84 ± 26.1548.89 ± 19.787
AL, CFB to Week 67-7.64 ± 26.8432.08 ± 8.333
AL, CFB to Week 70-6.80 ± 26.3342.56 ± 9.245
AL, CFB to Week 73-3.25 ± 25.6096.67 ± 13.801
AL, CFB to Week 76-4.88 ± 29.4022.22 ± 8.607
AL, CFB to Week 79-5.69 ± 28.7734.44 ± 11.729
AL, CFB to Week 82-5.56 ± 29.3724.44 ± 11.729
AL, CFB to Week 85-9.26 ± 29.3977.69 ± 14.618
AL, CFB to Week 88-9.26 ± 25.9565.13 ± 12.518
AL, CFB to Week 91-6.48 ± 30.67411.90 ± 21.111
AL, CFB to Week 94-4.63 ± 26.6102.78 ± 9.623
AL, CFB to Week 97-4.44 ± 28.6793.03 ± 10.050
AL, CFB to Week 100-4.76 ± 21.6073.33 ± 10.541
AL, CFB to Week 103-6.86 ± 24.3150.00 ± 0.000
AL, CFB to Week 106-7.07 ± 24.6614.76 ± 12.599
AL, CFB to Week 109-5.88 ± 20.8748.33 ± 23.570
AL, CFB to Week 112-11.11 ± 22.0304.76 ± 12.599
AL, CFB to Week 115-8.89 ± 21.3238.33 ± 15.430
AL, CFB to Week 118-3.33 ± 20.2480.00 ± 0.000
AL, CFB to Week 121-5.56 ± 27.2174.17 ± 11.785
AL, CFB to Week 124-3.85 ± 21.7605.56 ± 13.608
AL, CFB to Week 127-1.28 ± 17.5905.56 ± 13.608
AL, CFB to Week 130-5.33 ± 15.7530.00 ± 0.000
AL, CFB to Week 133-2.78 ± 16.7875.56 ± 13.608
AL, CFB to Week 1360.00 ± 18.2576.67 ± 14.907
AL, CFB to Week 1390.00 ± 14.9075.56 ± 13.608
AL, CFB to Week 142-6.06 ± 16.7038.33 ± 16.667
AL, CFB to Week 1453.70 ± 15.7136.67 ± 14.907
AL, CFB to Week 148-3.51 ± 18.9048.33 ± 16.667
AL, CFB to Week 151-3.17 ± 23.34516.67 ± 33.333
AL, CFB to Week 154-1.75 ± 23.5018.33 ± 16.667
AL, CFB to Week 1573.92 ± 16.16911.11 ± 19.245
AL, CFB to Week 1609.26 ± 22.3040.00 ± 0.000
AL, CFB to Week 1635.56 ± 23.57011.11 ± 19.245
AL, CFB to Week 1664.44 ± 17.2130.00 ± 0.000
AL, CFB to Week 1693.92 ± 16.16911.11 ± 19.245
AL, CFB to Week 1722.56 ± 21.35011.11 ± 19.245
AL, CFB to Week 1750.00 ± 20.10111.11 ± 19.245
AL, CFB to Week 1782.38 ± 15.8210.00 ± 0.000
AL, CFB to Week 1812.38 ± 15.82111.11 ± 19.245
AL, CFB to Week 1840.00 ± 14.90711.11 ± 19.245
AL, CFB to Week 1873.70 ± 26.05816.67 ± 23.570
AL, CFB to Week 190-3.33 ± 18.92211.11 ± 19.245
AL, CFB to Week 1930.00 ± 19.24511.11 ± 19.245
AL, CFB to Week 196-4.17 ± 21.36211.11 ± 19.245
AL, CFB to Week 1994.76 ± 12.59911.11 ± 19.245
AL, CFB to Week 202-3.70 ± 11.11111.11 ± 19.245
AL, CFB to Week 2050.00 ± 19.24516.67 ± 23.570
AL, CFB to Week 2080.00 ± 19.24516.67 ± 23.570
AL, CFB to Week 211-6.67 ± 14.9070.00 ± 0.000
AL, CFB to Week 2140.00 ± 0.00016.67 ± 23.570
AL, CFB to Week 2170.00 ± 0.00016.67 ± 23.570
AL, CFB to Week 220-16.67 ± 23.57016.67 ± 23.570
AL, CFB to Week 223-8.33 ± 16.66716.67 ± 23.570
AL, CFB to Week 226-11.11 ± 19.24533.33 ± NA
AL, CFB to Week 229-16.67 ± 23.57033.33 ± NA
AL, CFB to Week 232-11.11 ± 19.24533.33 ± NA
AL, CFB to Week 2350.00 ± 0.00033.33 ± NA
AL, CFB to Week 238—33.33 ± NA
AL, CFB to EOT (~242 weeks)4.27 ± 35.70310.26 ± 25.633
AL, CFB to LFU (~263 weeks)-5.31 ± 31.6353.33 ± 32.264
Constipation, CFB to Week 4-2.10 ± 24.54013.82 ± 27.692
Constipation, CFB to Week 7-0.46 ± 24.8419.40 ± 27.861
Constipation, CFB to Week 10-1.31 ± 22.7728.85 ± 28.010
Constipation, CFB to Week 13-2.45 ± 23.87713.79 ± 27.948
Constipation, CFB to Week 16-2.24 ± 24.25312.35 ± 27.697
Constipation, CFB to Week 19-0.72 ± 23.55912.00 ± 27.570
Constipation, CFB to Week 22-1.43 ± 21.9325.00 ± 23.327
Constipation, CFB to Week 25-2.93 ± 20.87511.76 ± 23.039
Constipation, CFB to Week 28-1.20 ± 21.74410.48 ± 19.422
Constipation, CFB to Week 31-2.16 ± 21.1779.09 ± 19.135
Constipation, CFB to Week 341.39 ± 24.6656.67 ± 13.608
Constipation, CFB to Week 37-2.94 ± 22.10716.00 ± 25.676
Constipation, CFB to Week 400.48 ± 23.73612.00 ± 21.257
Constipation, CFB to Week 43-1.93 ± 20.5199.52 ± 23.905
Constipation, CFB to Week 461.59 ± 27.7148.33 ± 22.771
Constipation, CFB to Week 49-4.23 ± 21.1607.41 ± 18.277
Constipation, CFB to Week 52-2.73 ± 18.5545.00 ± 19.571
Constipation, CFB to Week 55-4.02 ± 18.8127.02 ± 13.962
Constipation, CFB to Week 58-4.17 ± 20.16312.96 ± 30.548
Constipation, CFB to Week 61-2.72 ± 23.40911.11 ± 22.866
Constipation, CFB to Week 64-1.36 ± 19.19613.33 ± 24.560
Constipation, CFB to Week 67-1.39 ± 20.58114.58 ± 27.131
Constipation, CFB to Week 70-2.72 ± 19.04815.38 ± 25.875
Constipation, CFB to Week 73-2.44 ± 18.84213.33 ± 24.560
Constipation, CFB to Week 76-1.63 ± 23.51317.78 ± 27.794
Constipation, CFB to Week 79-5.69 ± 18.10813.33 ± 24.560
Constipation, CFB to Week 82-6.35 ± 24.68013.33 ± 24.560
Constipation, CFB to Week 85-6.48 ± 23.66410.26 ± 25.036
Constipation, CFB to Week 88-6.48 ± 20.80812.82 ± 21.681
Constipation, CFB to Week 91-4.63 ± 22.75216.67 ± 25.318
Constipation, CFB to Week 94-2.78 ± 18.47311.11 ± 16.412
Constipation, CFB to Week 97-6.67 ± 18.36215.15 ± 22.918
Constipation, CFB to Week 100-2.86 ± 24.74913.33 ± 17.213
Constipation, CFB to Week 103-4.90 ± 23.40216.67 ± 25.198
Constipation, CFB to Week 106-4.04 ± 21.66314.29 ± 17.817
Constipation, CFB to Week 109-3.92 ± 19.70312.50 ± 17.252
Constipation, CFB to Week 112-5.75 ± 20.0579.52 ± 16.265
Constipation, CFB to Week 115-7.78 ± 16.80012.50 ± 17.252
Constipation, CFB to Week 118-2.22 ± 21.3238.33 ± 15.430
Constipation, CFB to Week 1211.39 ± 26.8828.33 ± 15.430
Constipation, CFB to Week 124-2.56 ± 26.5385.56 ± 13.608
Constipation, CFB to Week 1270.00 ± 24.94411.11 ± 17.213
Constipation, CFB to Week 1301.33 ± 31.15113.33 ± 18.257
Constipation, CFB to Week 1335.56 ± 32.10327.78 ± 25.092
Constipation, CFB to Week 1363.17 ± 20.82913.33 ± 18.257
Constipation, CFB to Week 1393.17 ± 20.82916.67 ± 18.257
Constipation, CFB to Week 142-1.52 ± 12.50316.67 ± 19.245
Constipation, CFB to Week 145-1.85 ± 17.97713.33 ± 18.257
Constipation, CFB to Week 148-1.75 ± 20.7098.33 ± 16.667
Constipation, CFB to Week 151-1.59 ± 19.6538.33 ± 16.667
Constipation, CFB to Week 1543.51 ± 21.9288.33 ± 16.667
Constipation, CFB to Week 157-3.92 ± 20.00811.11 ± 19.245
Constipation, CFB to Week 1601.85 ± 21.3050.00 ± NA
Constipation, CFB to Week 1630.00 ± 22.86622.22 ± 19.245
Constipation, CFB to Week 1660.00 ± 21.82211.11 ± 19.245
Constipation, CFB to Week 1690.00 ± 20.41211.11 ± 19.245
Constipation, CFB to Week 1720.00 ± 23.57011.11 ± 19.245
Constipation, CFB to Week 1752.78 ± 36.12111.11 ± 19.245
Constipation, CFB to Week 178-2.38 ± 20.52411.11 ± 19.245
Constipation, CFB to Week 1812.38 ± 27.62522.22 ± 38.490
Constipation, CFB to Week 1849.09 ± 15.57011.11 ± 19.245
Constipation, CFB to Week 18714.81 ± 33.79333.33 ± 47.140
Constipation, CFB to Week 1903.33 ± 39.9070.00 ± 0.000
Constipation, CFB to Week 1930.00 ± 0.00011.11 ± 19.245
Constipation, CFB to Week 196-8.33 ± 23.57011.11 ± 19.245
Constipation, CFB to Week 1990.00 ± 0.00011.11 ± 19.245
Constipation, CFB to Week 202-7.41 ± 22.22211.11 ± 19.245
Constipation, CFB to Week 205-9.52 ± 25.19816.67 ± 23.570
Constipation, CFB to Week 208-9.52 ± 25.19816.67 ± 23.570
Constipation, CFB to Week 211-13.33 ± 29.81416.67 ± 23.570
Constipation, CFB to Week 214-22.22 ± 38.49016.67 ± 23.570
Constipation, CFB to Week 2170.00 ± 0.00016.67 ± 23.570
Constipation, CFB to Week 2200.00 ± 0.00016.67 ± 23.570
Constipation, CFB to Week 2230.00 ± 0.00016.67 ± 23.570
Constipation, CFB to Week 2260.00 ± 0.00033.33 ± NA
Constipation, CFB to Week 2290.00 ± 0.00033.33 ± NA
Constipation, CFB to Week 2320.00 ± 0.00033.33 ± NA
Constipation, CFB to Week 2350.00 ± 0.00033.33 ± NA
Constipation, CFB to Week 238—33.33 ± NA
Constipation, CFB to EOT (~242 weeks)3.70 ± 26.1808.72 ± 22.265
Constipation, CFB to LFU (~263 weeks)1.45 ± 25.8423.33 ± 26.269
Diarrhea, CFB to Week 4-4.17 ± 22.713-4.07 ± 20.548
Diarrhea, CFB to Week 7-3.91 ± 20.973-3.90 ± 21.612
Diarrhea, CFB to Week 10-4.43 ± 18.880-7.69 ± 18.418
Diarrhea, CFB to Week 13-5.11 ± 23.868-5.75 ± 18.875
Diarrhea, CFB to Week 16-6.60 ± 22.734-4.40 ± 21.719
Diarrhea, CFB to Week 19-5.56 ± 21.449-5.33 ± 15.591
Diarrhea, CFB to Week 22-4.86 ± 22.674-4.07 ± 26.029
Diarrhea, CFB to Week 25-5.07 ± 25.166-4.90 ± 23.402
Diarrhea, CFB to Week 28-5.95 ± 21.435-6.67 ± 22.579
Diarrhea, CFB to Week 31-6.41 ± 20.142-8.08 ± 18.690
Diarrhea, CFB to Week 34-1.37 ± 22.525-5.33 ± 15.753
Diarrhea, CFB to Week 37-3.48 ± 23.308-4.00 ± 14.657
Diarrhea, CFB to Week 40-3.81 ± 25.722-6.67 ± 13.608
Diarrhea, CFB to Week 43-1.43 ± 23.697-6.35 ± 17.059
Diarrhea, CFB to Week 46-7.29 ± 24.823-6.25 ± 13.437
Diarrhea, CFB to Week 49-6.25 ± 22.123-3.51 ± 10.510
Diarrhea, CFB to Week 52-3.17 ± 18.660-5.00 ± 12.212
Diarrhea, CFB to Week 55-3.33 ± 25.080-5.26 ± 12.488
Diarrhea, CFB to Week 58-4.68 ± 23.9370.00 ± 16.169
Diarrhea, CFB to Week 61-4.08 ± 24.1840.00 ± 11.433
Diarrhea, CFB to Week 64-8.50 ± 21.953-2.22 ± 8.607
Diarrhea, CFB to Week 67-7.48 ± 21.800-2.08 ± 14.751
Diarrhea, CFB to Week 70-6.00 ± 18.6750.00 ± 0.000
Diarrhea, CFB to Week 73-6.50 ± 23.828-2.22 ± 15.258
Diarrhea, CFB to Week 76-3.17 ± 23.058-4.44 ± 11.729
Diarrhea, CFB to Week 79-7.94 ± 24.205-4.44 ± 11.729
Diarrhea, CFB to Week 82-4.65 ± 25.801-4.44 ± 11.729
Diarrhea, CFB to Week 85-10.81 ± 24.912-2.56 ± 16.452
Diarrhea, CFB to Week 88-3.81 ± 31.072-2.56 ± 9.245
Diarrhea, CFB to Week 91-4.50 ± 25.0462.38 ± 15.821
Diarrhea, CFB to Week 94-8.33 ± 25.6660.00 ± 14.213
Diarrhea, CFB to Week 97-8.89 ± 26.164-3.03 ± 10.050
Diarrhea, CFB to Week 100-6.67 ± 25.3090.00 ± 15.713
Diarrhea, CFB to Week 103-8.82 ± 23.654-3.70 ± 11.111
Diarrhea, CFB to Week 106-8.08 ± 22.096-4.76 ± 12.599
Diarrhea, CFB to Week 109-8.82 ± 22.185-4.17 ± 11.785
Diarrhea, CFB to Week 112-10.00 ± 23.4070.00 ± 0.000
Diarrhea, CFB to Week 115-12.22 ± 23.9470.00 ± 17.817
Diarrhea, CFB to Week 118-12.22 ± 23.947-4.17 ± 11.785
Diarrhea, CFB to Week 121-10.67 ± 28.415-4.17 ± 11.785
Diarrhea, CFB to Week 124-10.26 ± 26.279-5.56 ± 13.608
Diarrhea, CFB to Week 127-8.97 ± 25.919-5.56 ± 13.608
Diarrhea, CFB to Week 130-8.00 ± 27.689-6.67 ± 14.907
Diarrhea, CFB to Week 133-12.50 ± 25.6560.00 ± 0.000
Diarrhea, CFB to Week 136-7.94 ± 25.6140.00 ± 0.000
Diarrhea, CFB to Week 139-7.94 ± 25.6140.00 ± 0.000
Diarrhea, CFB to Week 142-10.61 ± 23.8740.00 ± 0.000
Diarrhea, CFB to Week 145-9.26 ± 27.5480.00 ± 0.000
Diarrhea, CFB to Week 148-5.26 ± 31.9400.00 ± 0.000
Diarrhea, CFB to Week 151-9.52 ± 26.1250.00 ± 0.000
Diarrhea, CFB to Week 154-8.77 ± 24.4500.00 ± 0.000
Diarrhea, CFB to Week 157-3.92 ± 16.1690.00 ± 0.000
Diarrhea, CFB to Week 160-3.70 ± 15.7130.00 ± 0.000
Diarrhea, CFB to Week 163-5.56 ± 12.7830.00 ± 0.000
Diarrhea, CFB to Week 166-2.22 ± 15.2580.00 ± 0.000
Diarrhea, CFB to Week 169-5.88 ± 13.0980.00 ± 0.000
Diarrhea, CFB to Week 172-7.69 ± 14.6180.00 ± 0.000
Diarrhea, CFB to Week 175-5.56 ± 12.9750.00 ± 0.000
Diarrhea, CFB to Week 178-4.76 ± 12.1050.00 ± 0.000
Diarrhea, CFB to Week 1810.00 ± 13.0740.00 ± 0.000
Diarrhea, CFB to Week 184-6.06 ± 13.4840.00 ± 0.000
Diarrhea, CFB to Week 187-3.70 ± 20.0310.00 ± 0.000
Diarrhea, CFB to Week 190-7.41 ± 14.6990.00 ± 0.000
Diarrhea, CFB to Week 1934.76 ± 12.5990.00 ± 0.000
Diarrhea, CFB to Week 1960.00 ± 0.0000.00 ± 0.000
Diarrhea, CFB to Week 199-4.76 ± 12.5990.00 ± 0.000
Diarrhea, CFB to Week 202-3.70 ± 11.1110.00 ± 0.000
Diarrhea, CFB to Week 205-4.76 ± 12.5990.00 ± 0.000
Diarrhea, CFB to Week 208-4.76 ± 12.5990.00 ± 0.000
Diarrhea, CFB to Week 2110.00 ± 0.0000.00 ± 0.000
Diarrhea, CFB to Week 2140.00 ± 0.0000.00 ± 0.000
Diarrhea, CFB to Week 2170.00 ± 0.0000.00 ± 0.000
Diarrhea, CFB to Week 2200.00 ± 0.0000.00 ± 0.000
Diarrhea, CFB to Week 2230.00 ± 0.0000.00 ± 0.000
Diarrhea, CFB to Week 2260.00 ± 0.0000.00 ± NA
Diarrhea, CFB to Week 2290.00 ± 0.0000.00 ± NA
Diarrhea, CFB to Week 2320.00 ± 0.0000.00 ± NA
Diarrhea, CFB to Week 2350.00 ± 0.0000.00 ± NA
Diarrhea, CFB to Week 238—0.00 ± NA
Diarrhea, CFB to EOT (~242 weeks)-3.11 ± 23.464-3.54 ± 23.482
Diarrhea, CFB to LFU (~263 weeks)-3.86 ± 24.612-14.04 ± 23.083
FD, CFB to Week 4-3.22 ± 29.532-3.61 ± 26.551
FD, CFB to Week 7-3.88 ± 26.984-4.70 ± 21.970
FD, CFB to Week 10-1.04 ± 23.267-1.54 ± 23.885
FD, CFB to Week 130.61 ± 30.083-5.17 ± 23.197
FD, CFB to Week 160.65 ± 31.993-3.85 ± 24.391
FD, CFB to Week 19-2.46 ± 29.271-0.67 ± 22.827
FD, CFB to Week 22-1.06 ± 27.4140.00 ± 27.546
FD, CFB to Week 25-3.33 ± 30.0022.94 ± 26.423
FD, CFB to Week 28-2.81 ± 29.543-0.95 ± 24.899
FD, CFB to Week 31-3.07 ± 26.765-2.02 ± 26.272
FD, CFB to Week 34-3.70 ± 29.8960.00 ± 31.914
FD, CFB to Week 37-1.00 ± 28.996-2.67 ± 27.080
FD, CFB to Week 400.00 ± 35.441-2.67 ± 27.080
FD, CFB to Week 43-4.35 ± 29.100-6.35 ± 29.096
FD, CFB to Week 46-3.70 ± 31.7422.08 ± 22.669
FD, CFB to Week 49-3.17 ± 31.5170.00 ± 19.245
FD, CFB to Week 52-2.69 ± 29.752-3.33 ± 28.408
FD, CFB to Week 55-2.26 ± 32.674-5.26 ± 22.942
FD, CFB to Week 58-1.19 ± 34.2091.85 ± 26.746
FD, CFB to Week 61-2.67 ± 32.184-1.85 ± 21.305
FD, CFB to Week 64-4.00 ± 29.075-6.67 ± 31.371
FD, CFB to Week 67-1.36 ± 30.3980.00 ± 27.217
FD, CFB to Week 70-3.40 ± 34.187-5.13 ± 22.958
FD, CFB to Week 734.07 ± 35.115-2.22 ± 26.627
FD, CFB to Week 760.81 ± 34.5510.00 ± 25.198
FD, CFB to Week 790.00 ± 33.333-2.22 ± 23.458
FD, CFB to Week 823.17 ± 34.382-4.44 ± 21.331
FD, CFB to Week 85-1.85 ± 34.682-7.69 ± 24.167
FD, CFB to Week 881.85 ± 38.168-5.13 ± 22.958
FD, CFB to Week 91-1.80 ± 34.198-2.38 ± 24.335
FD, CFB to Week 94-1.85 ± 35.585-2.78 ± 30.011
FD, CFB to Week 971.11 ± 32.144-6.06 ± 25.025
FD, CFB to Week 1002.86 ± 35.582-10.00 ± 22.498
FD, CFB to Week 103-3.92 ± 34.587-18.52 ± 33.793
FD, CFB to Week 106-2.02 ± 34.298-9.52 ± 31.706
FD, CFB to Week 109-2.94 ± 32.169-12.50 ± 24.801
FD, CFB to Week 112-5.75 ± 30.949-14.29 ± 26.227
FD, CFB to Week 115-4.44 ± 34.722-12.50 ± 24.801
FD, CFB to Week 118-3.33 ± 33.160-8.33 ± 29.547
FD, CFB to Week 121-6.67 ± 30.429-12.50 ± 24.801
FD, CFB to Week 124-11.54 ± 29.728-16.67 ± 27.889
FD, CFB to Week 127-3.85 ± 33.102-5.56 ± 13.608
FD, CFB to Week 130-8.00 ± 30.852-6.67 ± 14.907
FD, CFB to Week 133-2.78 ± 33.932-16.67 ± 27.889
FD, CFB to Week 136-1.59 ± 35.709-6.67 ± 14.907
FD, CFB to Week 139-3.17 ± 34.809-16.67 ± 27.889
FD, CFB to Week 142-9.09 ± 32.824-8.33 ± 16.667
FD, CFB to Week 1450.00 ± 36.1550.00 ± 23.570
FD, CFB to Week 148-5.26 ± 29.945-8.33 ± 16.667
FD, CFB to Week 151-1.59 ± 37.232-8.33 ± 16.667
FD, CFB to Week 154-1.75 ± 39.2420.00 ± 27.217
FD, CFB to Week 1575.88 ± 24.2540.00 ± 33.333
FD, CFB to Week 1607.41 ± 24.403-11.11 ± 19.245
FD, CFB to Week 163-3.70 ± 22.547-11.11 ± 19.245
FD, CFB to Week 1662.22 ± 29.4570.00 ± 33.333
FD, CFB to Week 1691.96 ± 29.9780.00 ± 33.333
FD, CFB to Week 172-5.13 ± 26.6880.00 ± 33.333
FD, CFB to Week 1750.00 ± 31.782-11.11 ± 19.245
FD, CFB to Week 178-2.38 ± 30.562-11.11 ± 19.245
FD, CFB to Week 181-2.38 ± 20.5240.00 ± 33.333
FD, CFB to Week 1840.00 ± 29.8140.00 ± 33.333
FD, CFB to Week 187-3.70 ± 20.0310.00 ± 0.000
FD, CFB to Week 190-7.41 ± 32.394-11.11 ± 19.245
FD, CFB to Week 193-9.52 ± 25.198-11.11 ± 19.245
FD, CFB to Week 196-4.17 ± 27.817-11.11 ± 19.245
FD, CFB to Week 199-4.76 ± 12.599-11.11 ± 19.245
FD, CFB to Week 202-3.70 ± 38.8890.00 ± 33.333
FD, CFB to Week 205-9.52 ± 31.706-16.67 ± 23.570
FD, CFB to Week 208-14.29 ± 32.530-16.67 ± 23.570
FD, CFB to Week 2110.00 ± 47.140-16.67 ± 23.570
FD, CFB to Week 21422.22 ± 38.490-16.67 ± 23.570
FD, CFB to Week 217-16.67 ± 23.570-16.67 ± 23.570
FD, CFB to Week 220-16.67 ± 23.570-16.67 ± 23.570
FD, CFB to Week 223-8.33 ± 16.667-16.67 ± 23.570
FD, CFB to Week 226-11.11 ± 19.2450.00 ± NA
FD, CFB to Week 229-33.33 ± 47.1400.00 ± NA
FD, CFB to Week 232-22.22 ± 38.4900.00 ± NA
FD, CFB to Week 2350.00 ± 0.0000.00 ± NA
FD, CFB to Week 238—0.00 ± NA
FD, CFB to EOT (~242 weeks)2.82 ± 32.490-1.01 ± 28.627
FD, CFB to LFU (~263 weeks)-1.47 ± 37.516-1.67 ± 36.635
SecondaryChange From Baseline (CFB) in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score

The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. The module comprised of 20 questions that addressed four myeloma-specific HRQoL domains: disease symptoms (DS), side effects of treatment (SET), future perspective (FP) and body image (BI). Responses are 1 to 4. Scores were averaged and scales were transformed to 0 to 100 scale. A high score for disease symptoms and side effects of treatment represented a high level of symptomatology or problems, whereas a high score for future perspective and body image represented better outcomes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238, End of Treatment (~242 weeks) and Follow up (~263 weeks)
Reported as:
Mean · Scores on Scale
Change From Baseline (CFB) in EORTC QLQ 20-item Multiple Myeloma Module (MY20) Score
Scores on ScaleBelantamab MafodotinPomalidomide Plus Dexamethasone
BI, CFB to Week 47.07 ± 21.6637.14 ± 19.298
BI, CFB to Week 7-4.44 ± 27.3102.08 ± 19.124
BI, CFB to Week 10-1.23 ± 21.6455.56 ± 19.245
BI, CFB to Week 131.33 ± 20.3675.13 ± 22.958
BI, CFB to Week 16-4.17 ± 26.580-4.44 ± 24.774
BI, CFB to Week 19-3.03 ± 20.33911.11 ± 21.711
BI, CFB to Week 225.80 ± 21.6780.00 ± 14.213
BI, CFB to Week 25-1.39 ± 23.0080.00 ± 21.082
BI, CFB to Week 284.76 ± 21.8220.00 ± 25.198
BI, CFB to Week 314.76 ± 24.2348.33 ± 23.570
BI, CFB to Week 345.26 ± 25.4914.76 ± 23.002
BI, CFB to Week 370.00 ± 28.006-4.17 ± 21.362
BI, CFB to Week 403.70 ± 22.5470.00 ± 25.198
BI, CFB to Week 431.85 ± 21.3050.00 ± 27.217
BI, CFB to Week 464.17 ± 16.6676.67 ± 27.889
BI, CFB to Week 495.88 ± 24.254-5.56 ± 32.773
BI, CFB to Week 522.38 ± 20.5244.76 ± 23.002
BI, CFB to Week 55-5.13 ± 12.518-4.76 ± 35.635
BI, CFB to Week 580.00 ± 22.6464.76 ± 23.002
BI, CFB to Week 61-2.38 ± 15.8210.00 ± 27.217
BI, CFB to Week 645.13 ± 22.9586.67 ± 27.889
BI, CFB to Week 67-2.38 ± 20.5240.00 ± 33.333
BI, CFB to Week 700.00 ± 19.2450.00 ± 33.333
BI, CFB to Week 73-6.67 ± 21.0826.67 ± 27.889
BI, CFB to Week 76-8.33 ± 25.1260.00 ± 33.333
BI, CFB to Week 793.03 ± 27.7070.00 ± 33.333
BI, CFB to Week 829.09 ± 21.5566.67 ± 27.889
BI, CFB to Week 854.17 ± 21.3620.00 ± 33.333
BI, CFB to Week 88-15.15 ± 22.9180.00 ± 33.333
BI, CFB to Week 91-8.33 ± 15.4300.00 ± 33.333
BI, CFB to Week 94-3.33 ± 18.9220.00 ± 33.333
BI, CFB to Week 974.17 ± 11.7850.00 ± 33.333
BI, CFB to Week 1009.52 ± 25.198-11.11 ± 19.245
BI, CFB to Week 1030.00 ± 25.198-22.22 ± 19.245
BI, CFB to Week 1065.56 ± 25.092-33.33 ± NA
BI, CFB to Week 1090.00 ± 25.198-11.11 ± 38.490
BI, CFB to Week 11211.11 ± 27.217-33.33 ± 0.000
BI, CFB to Week 1154.76 ± 23.002-22.22 ± 19.245
BI, CFB to Week 118-4.76 ± 23.002-22.22 ± 19.245
BI, CFB to Week 1210.00 ± 19.245-33.33 ± 33.333
BI, CFB to Week 124-13.33 ± 18.257-33.33 ± 0.000
BI, CFB to Week 1270.00 ± 21.0820.00 ± 0.00
BI, CFB to Week 1305.56 ± 25.0920.00 ± NA
BI, CFB to Week 1336.67 ± 14.907-16.67 ± 23.570
BI, CFB to Week 1360.00 ± 0.000.00 ± NA
BI, CFB to Week 139-8.33 ± 16.667-33.33 ± 47.140
BI, CFB to Week 1428.33 ± 16.667—
BI, CFB to Week 14511.11 ± 19.2450.00 ± NA
BI, CFB to Week 1480.00 ± 33.3330.00 ± NA
BI, CFB to Week 15122.22 ± 19.2450.00 ± NA
BI, CFB to Week 154-16.67 ± 23.5700.00 ± NA
BI, CFB to Week 1570.00 ± 27.217—
BI, CFB to Week 16011.11 ± 19.245—
BI, CFB to Week 16316.67 ± 23.570—
BI, CFB to Week 16616.67 ± 23.570—
BI, CFB to Week 16916.67 ± 23.570—
BI, CFB to Week 17233.33 ± NA—
BI, CFB to Week 17533.33 ± NA—
BI, CFB to Week 17833.33 ± NA—
BI, CFB to Week 18133.33 ± NA—
BI, CFB to EOT (~242 weeks)-10.14 ± 29.189-5.13 ± 18.490
BI, CFB to LFU (~263 weeks)-11.11 ± 27.217-11.11 ± 19.245
DS, CFB to Week 4-2.54 ± 15.169-3.16 ± 14.272
DS, CFB to Week 7-2.38 ± 16.226-5.76 ± 16.668
DS, CFB to Week 10-3.71 ± 16.488-4.82 ± 17.445
DS, CFB to Week 13-4.67 ± 18.590-7.05 ± 16.100
DS, CFB to Week 16-5.51 ± 17.544-5.85 ± 18.479
DS, CFB to Week 19-5.05 ± 20.806-5.67 ± 19.650
DS, CFB to Week 22-4.08 ± 19.689-6.46 ± 18.330
DS, CFB to Week 25-6.92 ± 16.442-6.54 ± 16.382
DS, CFB to Week 28-4.01 ± 19.672-7.68 ± 19.487
DS, CFB to Week 31-4.28 ± 18.536-7.24 ± 18.865
DS, CFB to Week 34-4.21 ± 16.739-6.25 ± 11.735
DS, CFB to Week 37-7.12 ± 19.892-3.47 ± 14.075
DS, CFB to Week 40-8.32 ± 18.363-3.04 ± 12.989
DS, CFB to Week 43-7.50 ± 19.751-3.09 ± 14.664
DS, CFB to Week 46-9.01 ± 17.512-3.85 ± 16.879
DS, CFB to Week 49-6.74 ± 17.359-3.13 ± 20.883
DS, CFB to Week 52-8.83 ± 17.943-5.88 ± 14.760
DS, CFB to Week 55-7.01 ± 19.811-1.39 ± 14.558
DS, CFB to Week 58-7.08 ± 20.435-1.85 ± 18.505
DS, CFB to Week 61-7.02 ± 19.8270.35 ± 16.161
DS, CFB to Week 64-6.39 ± 19.010-5.95 ± 16.803
DS, CFB to Week 67-11.04 ± 16.693-5.56 ± 18.426
DS, CFB to Week 70-12.64 ± 16.959-8.12 ± 15.976
DS, CFB to Week 73-9.36 ± 15.274-2.78 ± 19.214
DS, CFB to Week 76-7.57 ± 15.562-5.19 ± 13.684
DS, CFB to Week 79-8.39 ± 15.938-8.67 ± 13.790
DS, CFB to Week 82-6.46 ± 15.596-10.00 ± 15.459
DS, CFB to Week 85-7.69 ± 14.917-10.19 ± 18.628
DS, CFB to Week 88-8.77 ± 16.228-11.57 ± 17.957
DS, CFB to Week 91-8.26 ± 17.888-0.46 ± 23.145
DS, CFB to Week 94-10.77 ± 17.865-4.04 ± 20.502
DS, CFB to Week 97-8.30 ± 14.783-7.22 ± 15.505
DS, CFB to Week 100-8.86 ± 18.135-3.89 ± 22.688
DS, CFB to Week 103-8.79 ± 17.518-2.47 ± 19.859
DS, CFB to Week 106-9.39 ± 18.811-0.93 ± 17.362
DS, CFB to Week 109-7.81 ± 14.082-2.78 ± 20.574
DS, CFB to Week 112-11.30 ± 15.1771.59 ± 24.993
DS, CFB to Week 115-7.41 ± 14.468-2.08 ± 15.974
DS, CFB to Week 118-6.67 ± 16.2720.00 ± 21.207
DS, CFB to Week 121-4.91 ± 25.256-2.08 ± 23.181
DS, CFB to Week 124-11.56 ± 17.192-6.48 ± 20.005
DS, CFB to Week 127-7.91 ± 18.337-5.56 ± 19.245
DS, CFB to Week 130-12.00 ± 14.316-1.11 ± 23.040
DS, CFB to Week 133-11.34 ± 15.497-4.63 ± 25.680
DS, CFB to Week 136-8.99 ± 19.283-7.78 ± 20.638
DS, CFB to Week 139-10.05 ± 14.339-11.11 ± 22.222
DS, CFB to Week 142-7.83 ± 13.131-5.56 ± 27.962
DS, CFB to Week 145-7.72 ± 16.185-3.33 ± 22.083
DS, CFB to Week 148-7.89 ± 16.283-5.56 ± 27.962
DS, CFB to Week 151-10.32 ± 15.643-8.33 ± 20.538
DS, CFB to Week 154-9.26 ± 17.5682.78 ± 31.914
DS, CFB to Week 157-10.13 ± 16.344-5.56 ± 36.430
DS, CFB to Week 160-5.56 ± 20.0765.56 ± 52.997
DS, CFB to Week 163-9.26 ± 19.339-1.85 ± 36.147
DS, CFB to Week 166-11.11 ± 18.306-3.70 ± 39.021
DS, CFB to Week 169-7.84 ± 17.684-7.41 ± 33.945
DS, CFB to Week 172-16.24 ± 16.738-9.26 ± 31.590
DS, CFB to Week 175-13.43 ± 17.157-7.41 ± 33.945
DS, CFB to Week 178-10.32 ± 17.549-16.67 ± 24.216
DS, CFB to Week 181-9.92 ± 15.281-9.26 ± 31.590
DS, CFB to Week 184-2.53 ± 19.620-5.56 ± 36.430
DS, CFB to Week 187-2.47 ± 16.224-5.56 ± 54.997
DS, CFB to Week 190-5.00 ± 21.667-3.70 ± 39.021
DS, CFB to Week 193-3.17 ± 7.069-9.26 ± 31.590
DS, CFB to Week 196-12.35 ± 17.073-13.70 ± 26.674
DS, CFB to Week 199-2.38 ± 14.649-5.56 ± 36.430
DS, CFB to Week 202-9.88 ± 18.794-7.41 ± 33.945
DS, CFB to Week 205-11.11 ± 23.13013.89 ± 19.642
DS, CFB to Week 208-11.90 ± 21.8558.33 ± 11.785
DS, CFB to Week 211-11.11 ± 23.89513.89 ± 19.642
DS, CFB to Week 214-14.81 ± 30.59813.89 ± 19.642
DS, CFB to Week 2170.00 ± 0.00013.89 ± 19.642
DS, CFB to Week 220-2.78 ± 3.9285.56 ± 7.857
DS, CFB to Week 223-1.39 ± 6.991-2.78 ± 3.928
DS, CFB to Week 226-5.56 ± 9.62316.67 ± NA
DS, CFB to Week 229-8.33 ± 11.78516.67 ± NA
DS, CFB to Week 232-1.85 ± 8.48622.22 ± NA
DS, CFB to Week 2350.00 ± 0.00016.67 ± NA
DS, CFB to Week 238—16.67 ± NA
DS, CFB to EOT (~242 weeks)1.44 ± 21.907-1.23 ± 18.763
DS, CFB to LFU (~263 weeks)-2.12 ± 22.907-15.93 ± 23.370
SET, CFB to Week 4-2.18 ± 7.6593.92 ± 11.722
SET, CFB to Week 70.69 ± 8.787-1.90 ± 8.875
SET, CFB to Week 100.09 ± 11.303-0.90 ± 11.107
SET, CFB to Week 13-1.33 ± 9.1460.19 ± 14.300
SET, CFB to Week 16-1.81 ± 9.856-1.98 ± 12.199
SET, CFB to Week 19-0.22 ± 8.596-2.16 ± 14.177
SET, CFB to Week 22-1.16 ± 8.625-2.58 ± 12.207
SET, CFB to Week 25-3.23 ± 9.7814.65 ± 11.792
SET, CFB to Week 28-2.49 ± 6.870-3.10 ± 8.196
SET, CFB to Week 31-2.77 ± 9.936-4.77 ± 13.877
SET, CFB to Week 34-0.76 ± 7.892-6.24 ± 10.216
SET, CFB to Week 37-2.08 ± 8.5792.31 ± 9.645
SET, CFB to Week 40-3.09 ± 11.054-1.81 ± 7.305
SET, CFB to Week 43-2.37 ± 11.113-1.64 ± 10.541
SET, CFB to Week 46-3.06 ± 8.8283.48 ± 3.606
SET, CFB to Week 49-2.18 ± 6.8751.17 ± 7.617
SET, CFB to Week 52-4.10 ± 6.707-4.50 ± 7.433
SET, CFB to Week 55-3.79 ± 8.101-0.11 ± 8.475
SET, CFB to Week 580.26 ± 10.728-3.07 ± 6.200
SET, CFB to Week 61-1.01 ± 9.369-0.21 ± 8.462
SET, CFB to Week 64-1.08 ± 7.905-0.30 ± 6.150
SET, CFB to Week 67-2.57 ± 7.500-1.70 ± 6.228
SET, CFB to Week 70-1.40 ± 8.276-3.63 ± 5.168
SET, CFB to Week 730.54 ± 10.793-0.30 ± 5.402
SET, CFB to Week 76-0.06 ± 7.798-1.04 ± 6.189
SET, CFB to Week 79-3.80 ± 8.576-2.37 ± 4.897
SET, CFB to Week 82-2.69 ± 7.496-5.04 ± 5.320
SET, CFB to Week 851.44 ± 9.980-1.36 ± 4.777
SET, CFB to Week 881.16 ± 8.321-1.36 ± 8.049
SET, CFB to Week 91-0.74 ± 8.6546.42 ± 3.361
SET, CFB to Week 94-2.07 ± 8.985-0.25 ± 2.971
SET, CFB to Week 97-2.64 ± 8.772-0.25 ± 8.545
SET, CFB to Week 100-3.39 ± 10.142-1.36 ± 8.049
SET, CFB to Week 103-0.93 ± 9.147-1.36 ± 1.750
SET, CFB to Week 106-1.85 ± 5.781-0.74 ± NA
SET, CFB to Week 109-0.93 ± 8.508-5.80 ± 6.833
SET, CFB to Week 112-2.84 ± 7.138-5.37 ± 15.975
SET, CFB to Week 115-2.65 ± 9.475-3.46 ± 8.837
SET, CFB to Week 1181.43 ± 10.7206.54 ± 5.242
SET, CFB to Week 1211.11 ± 10.0050.12 ± 12.408
SET, CFB to Week 1244.67 ± 14.519-2.04 ± 20.689
SET, CFB to Week 1272.65 ± 8.8166.67 ± 1.048
SET, CFB to Week 1302.35 ± 7.343-0.74 ± NA
SET, CFB to Week 1330.59 ± 8.2012.78 ± 3.928
SET, CFB to Week 1365.90 ± 3.88511.11 ± NA
SET, CFB to Week 1399.63 ± 10.1024.63 ± 3.928
SET, CFB to Week 1427.31 ± 8.003—
SET, CFB to Week 1459.88 ± 4.2773.70 ± NA
SET, CFB to Week 1482.96 ± 8.5433.70 ± NA
SET, CFB to Week 1517.41 ± 3.7043.70 ± NA
SET, CFB to Week 1549.26 ± 2.6193.70 ± NA
SET, CFB to Week 1576.85 ± 6.985—
SET, CFB to Week 1606.67 ± 4.857—
SET, CFB to Week 1636.30 ± 6.809—
SET, CFB to Week 1665.56 ± 2.619—
SET, CFB to Week 1697.41 ± 5.238—
SET, CFB to Week 1723.70 ± NA—
SET, CFB to Week 17511.11 ± NA—
SET, CFB to Week 1780.00 ± NA—
SET, CFB to Week 1810.00 ± NA—
SET, CFB to EOT (~242 weeks)1.73 ± 13.594-1.34 ± 15.436
SET, CFB to LFU (~263 weeks)4.62 ± 12.90514.69 ± 21.787
FP, CFB to Week 4-3.37 ± 18.9393.97 ± 14.194
FP, CFB to Week 71.48 ± 19.9477.64 ± 9.702
FP, CFB to Week 101.65 ± 19.17212.96 ± 18.247
FP, CFB to Week 131.33 ± 20.36715.38 ± 18.447
FP, CFB to Week 160.93 ± 17.31215.56 ± 23.682
FP, CFB to Week 198.08 ± 17.20716.67 ± 22.473
FP, CFB to Week 226.28 ± 12.9009.26 ± 24.995
FP, CFB to Week 256.48 ± 19.9085.56 ± 11.653
FP, CFB to Week 289.52 ± 17.31511.11 ± 14.548
FP, CFB to Week 318.47 ± 24.06412.50 ± 20.945
FP, CFB to Week 349.36 ± 17.47611.11 ± 20.286
FP, CFB to Week 3712.35 ± 20.8356.94 ± 23.710
FP, CFB to Week 409.88 ± 23.7664.17 ± 22.954
FP, CFB to Week 4314.20 ± 24.6416.35 ± 27.108
FP, CFB to Week 466.94 ± 20.638-4.44 ± 30.021
FP, CFB to Week 4913.07 ± 24.2917.41 ± 19.458
FP, CFB to Week 526.35 ± 18.34314.29 ± 19.994
FP, CFB to Week 558.55 ± 17.0664.76 ± 21.138
FP, CFB to Week 58-3.17 ± 19.6987.94 ± 16.623
FP, CFB to Week 612.38 ± 20.05612.70 ± 23.508
FP, CFB to Week 641.71 ± 18.61813.33 ± 24.088
FP, CFB to Week 673.97 ± 16.07615.56 ± 23.040
FP, CFB to Week 705.13 ± 15.4604.44 ± 16.851
FP, CFB to Week 73-2.22 ± 20.82011.11 ± 19.245
FP, CFB to Week 764.63 ± 19.22111.11 ± 26.058
FP, CFB to Week 791.01 ± 16.81711.11 ± 26.058
FP, CFB to Week 823.03 ± 19.93313.33 ± 25.337
FP, CFB to Week 85-1.39 ± 28.7530.00 ± 19.245
FP, CFB to Week 88-2.02 ± 24.2513.70 ± 12.830
FP, CFB to Week 911.39 ± 25.5020.00 ± 11.111
FP, CFB to Week 944.44 ± 22.3453.70 ± 12.830
FP, CFB to Week 9712.50 ± 18.245-11.11 ± 11.111
FP, CFB to Week 1004.76 ± 17.982-7.41 ± 16.973
FP, CFB to Week 1031.39 ± 22.567-14.81 ± 6.415
FP, CFB to Week 1063.70 ± 13.4560.00 ± NA
FP, CFB to Week 1092.78 ± 14.242-18.52 ± 6.415
FP, CFB to Week 1125.56 ± 20.787-11.11 ± 15.713
FP, CFB to Week 1156.35 ± 17.982-18.52 ± 6.415
FP, CFB to Week 118-3.17 ± 12.363-18.52 ± 6.415
FP, CFB to Week 1216.35 ± 16.798-18.52 ± 6.415
FP, CFB to Week 124-11.11 ± 26.058-16.67 ± 7.857
FP, CFB to Week 1271.85 ± 12.989-16.67 ± 7.857
FP, CFB to Week 1301.85 ± 16.3550.00 ± NA
FP, CFB to Week 1330.00 ± 15.713-22.22 ± 0.000
FP, CFB to Week 1360.00 ± 29.397-22.22 ± NA
FP, CFB to Week 1395.56 ± 19.245-22.22 ± 0.000
FP, CFB to Week 1425.56 ± 21.276—
FP, CFB to Week 1457.41 ± 25.660-22.22 ± NA
FP, CFB to Week 1487.41 ± 16.973-22.22 ± NA
FP, CFB to Week 15111.11 ± 19.245-22.22 ± NA
FP, CFB to Week 15411.11 ± 31.427-22.22
FP, CFB to Week 15713.89 ± 16.667—
FP, CFB to Week 1607.41 ± 16.973—
FP, CFB to Week 1630.00 ± 15.713—
FP, CFB to Week 16616.67 ± 7.857—
FP, CFB to Week 16911.11 ± 0.000—
FP, CFB to Week 172-11.11 ± NA—
FP, CFB to Week 175-11.11 ± NA—
FP, CFB to Week 17811.11 ± NA—
FP, CFB to Week 18122.22 ± NA—
FP, CFB to EOT (~242 weeks)-14.01 ± 32.862-5.13 ± 29.262
FP, CFB to LFU (~263 weeks)-6.67 ± 20.053-25.93 ± 27.962
SecondaryChange From Baseline (CFB) in EORTC IL52 Score

European Organization for Research and Treatment of Cancer Item Library 52 (EORTC-QLQ-IL52) is disease symptoms domain from EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module) (EORTC QLQ-MY20). Disease symptoms domain of IL52 contain 6 items covering following concepts: bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. IL52 items are scored on 1 to 4 Likert-type scale, where 1 = Not at all, 2 = A little, 3 = Quite a bit, and 4 = Very much. A raw score is then calculated as mean of completed item responses across 6 disease symptom items. For symptom scales, this raw score is linearly transformed to a 0 to 100 scale using the formula: \[(raw score - 1) / 3\] × 100. Under this approach, a score of 0 indicates no symptoms across items, while a score of 100 indicates the highest level of symptom burden. Accordingly, higher scores indicate greater symptom burden or worse disease symptoms

Time frame:
Baseline (Day 1), every three weeks(Q3W) starting from week 4 until week 238
Reported as:
Least squares mean · Scores on Scale
Change From Baseline (CFB) in EORTC IL52 Score
Scores on ScaleBelantamab MafodotinPomalidomide Plus Dexamethasone
Disease Symptoms, CFB to Week 4-1.6 (-3.9 to 0.7)-2.8 (-6.2 to 0.6)
Disease Symptoms, CFB to Week 7-1.4 (-4.0 to 1.1)-4.2 (-7.8 to -0.6)
Disease Symptoms, CFB to Week 10-1.5 (-4.3 to 1.3)-1.7 (-5.7 to 2.2)
Disease Symptoms, CFB to Week 13-2.1 (-4.9 to 0.7)-4.1 (-8.0 to -0.3)
Disease Symptoms, CFB to Week 16-4.0 (-7.0 to -1.1)-3.3 (-7.3 to 0.8)
Disease Symptoms, CFB to Week 19-2.9 (-6.3 to 0.5)-3.7 (-8.5 to 1.0)
Disease Symptoms, CFB to Week 22-2.8 (-6.1 to 0.5)-4.7 (-9.5 to 0.1)
Disease Symptoms, CFB to Week 25-4.0 (-7.0 to -1.1)-3.6 (-8.2 to 0.9)
Disease Symptoms, Week 28-2.3 (-5.6 to 0.9)-6.4 (-11.3 to -1.4)
Disease Symptoms, CFB to Week 31-2.7 (-5.9 to 0.6)-7.2 (-12.1 to -2.2)
Disease Symptoms, CFB to Week 34-2.8 (-5.7 to 0.2)-8.1 (-12.9 to -3.2)
Disease Symptoms, CFB to Week 37-6.2 (-9.6 to -2.8)-7.1 (-12.9 to -1.4)
Disease Symptoms, CFB to Week 40-5.9 (-9.0 to -2.7)-6.8 (-12.3 to -1.3)
Disease Symptoms, CFB to Week 43-4.9 (-8.6 to -1.2)-8.6 (-15.6 to -1.6)
Disease Symptoms, CFB to Week 46-7.1 (-10.0 to -4.1)-8.4 (-14.4 to -2.3)
Disease Symptoms, CFB to Week 49-5.4 (-8.9 to -1.9)-8.3 (-15.2 to -1.3)
Disease Symptoms, CFB to Week 52-7.7 (-10.7 to -4.7)-10.0 (-15.8 to -4.1)
Disease Symptoms, CFB to Week 55-7.6 (-11.2 to -3.9)-5.4 (-12.5 to 1.7)
Disease Symptoms, CFB to Week 58-6.5 (-10.7 to -2.3)-5.5 (-13.6 to 2.6)
Disease Symptoms, CFB to Week 61-6.5 (-10.6 to -2.4)-3.2 (-10.7 to 4.4)
Disease Symptoms, CFB to Week 64-6.7 (-10.7 to -2.8)-9.4 (-16.8 to -2.0)
Disease Symptoms, CFB to Week 67-9.9 (-13.3 to -6.5)-7.9 (-14.1 to -1.7)
Disease Symptoms, CFB to Week 70-10.7 (-13.8 to -7.6)-12.3 (-18.1 to -6.5)
Disease Symptoms, CFB to Week 73-8.7 (-12.7 to -4.8)-6.4 (-13.4 to 0.6)
Disease Symptoms, CFB to Week 76-7.2 (-11.0 to -3.5)-7.0 (-13.6 to -0.5)
Disease Symptoms, CFB to Week 79-8.8 (-12.6 to -5.0)-10.5 (-17.1 to -3.8)
Disease Symptoms, CFB to Week 82-6.9 (-10.5 to -3.2)-11.9 (-18.3 to -5.4)
Disease Symptoms, CFB to Week 85-7.1 (-10.7 to -3.5)-13.0 (-19.4 to -6.7)
Disease Symptoms, CFB to Week 88-6.7 (-10.5 to -2.9)-11.4 (-18.0 to -4.7)
Disease Symptoms, CFB to Week 91-7.0 (-11.7 to -2.4)-3.8 (-12.0 to 4.4)
Disease Symptoms, CFB to Week 94-8.9 (-12.8 to -5.0)-9.1 (-16.2 to -2.0)
Disease Symptoms, CFB to Week 97-6.4 (-10.6 to -2.1)-7.6 (-15.2 to 0.0)
Disease Symptoms, CFB to Week 100-7.8 (-12.7 to -3.0)-7.5 (-16.7 to 1.6)
Disease Symptoms, CFB to Week 103-7.8 (-12.2 to -3.3)-4.7 (-13.3 to 4.0)
Disease Symptoms, CFB to Week 106-7.9 (-12.2 to -3.6)-7.2 (-16.4 to 2.0)
Disease Symptoms, CFB to Week 109-7.7 (-11.7 to -3.6)-6.1 (-14.4 to 2.2)
Disease Symptoms, CFB to Week 112-9.9 (-14.4 to -5.3)-1.4 (-10.7 to 7.9)
Disease Symptoms, CFB to Week 115-7.9 (-12.0 to -3.7)-5.0 (-13.4 to 3.3)
Disease Symptoms, CFB to Week 118-6.5 (-11.7 to -1.3)-3.1 (-13.4 to 7.3)
Disease Symptoms, CFB to Week 121-2.3 (-10.0 to 5.3)-6.7 (-21.3 to 7.8)
Disease Symptoms, CFB to Week 124-11.3 (-16.1 to -6.5)-7.3 (-16.9 to 2.3)
Disease Symptoms, CFB to Week 127-7.5 (-13.2 to -1.8)-10.9 (-22.6 to 0.7)
Disease Symptoms, CFB to Week 130-11.5 (-16.0 to -6.9)-5.1 (-14.6 to 4.5)
Disease Symptoms, CFB to Week 133-10.2 (-16.0 to -4.4)-4.2 (-15.8 to 7.5)
Disease Symptoms, CFB to Week 136-8.9 (-14.8 to -3.1)-14.4 (-26.4 to -2.4)
Disease Symptoms, CFB to Week 139-11.5 (-15.6 to -7.3)-14.0 (-22.2 to -5.8)
Disease Symptoms, CFB to Week 142-11.9 (-17.0 to -6.8)-11.1 (-22.1 to -0.1)
Disease Symptoms, CFB to Week 145-10.0 (-14.7 to -5.2)-9.6 (-19.3 to 0.1)
Disease Symptoms, CFB to Week 148-8.7 (-14.3 to -3.0)-10.1 (-22.5 to 2.3)
Disease Symptoms, CFB to Week 151-11.2 (-15.4 to -7.0)-13.0 (-22.6 to -3.3)
Disease Symptoms, CFB to Week 154-8.8 (-14.9 to -2.8)-1.5 (-15.1 to 12.1)
Disease Symptoms, CFB to Week 157-11.8 (-16.5 to -7.1)-9.1 (-20.3 to 2.1)
Disease Symptoms, CFB to Week 160-8.0 (-15.2 to -0.9)1.8 (-15.6 to 19.2)
Disease Symptoms, CFB to Week 163-10.7 (-16.1 to -5.3)-4.6 (-17.9 to 8.6)
Disease Symptoms, CFB to Week 166-12.8 (-18.6 to -7.0)-6.0 (-19.8 to 7.8)
Disease Symptoms, CFB to Week 169-10.0 (-15.8 to -4.1)-9.4 (-23.3 to 4.5)
Disease Symptoms, CFB to Week 172-15.0 (-19.9 to -10.0)-11.1 (-22.1 to 0.0)
Disease Symptoms, CFB to Week 175-16.1 (-21.4 to -10.8)-9.4 (-20.6 to 1.9)
Disease Symptoms, CFB to Week 178-15.9 (-19.5 to -12.4)-18.8 (-26.2 to -11.5)
Disease Symptoms, CFB to Week 181-14.5 (-20.6 to -8.3)-11.1 (-23.8 to 1.7)
Disease Symptoms, CFB to Week 184-12.4 (-22.2 to -2.5)-8.1 (-26.8 to 10.6)
Disease Symptoms, CFB to Week 187-7.8 (-20.2 to 4.6)-8.3 (-33.4 to 16.8)
Disease Symptoms, CFB to Week 190-6.7 (-17.5 to 4.1)-5.2 (-25.9 to 15.5)
Disease Symptoms, CFB to Week 193-14.0 (-22.7 to -5.2)-11.3 (-23.7 to 1.1)
Disease Symptoms, CFB to Week 196-19.8 (-24.0 to -15.6)-16.0 (-23.1 to -8.9)
Disease Symptoms, CFB to Week 199-11.8 (-25.2 to 1.6)-7.6 (-25.9 to 10.8)
Disease Symptoms, CFB to Week 202-17.9 (-26.3 to -9.4)-9.9 (-23.6 to 3.9)
Disease Symptoms, CFB to Week 205NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 208NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 211NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 214NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 217NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 220NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 223NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 226NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 229NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 232NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 235NA (NA to NA)NA (NA to NA)
Disease Symptoms, CFB to Week 238—NA (NA to NA)
SecondaryNumber of Participants With Minimal Residual Disease (MRD) Negativity Rate

MRD negativity rate is defined as the percentage of participants who are MRD negative by Next generation sequencing (NGS) method. The number of participants with MRD negativity has been presented

Time frame:
Up to approximately 263 weeks
Reported as:
Count of participants · Participants
Number of Participants With Minimal Residual Disease (MRD) Negativity Rate
ParticipantsBelantamab MafodotinPomalidomide Plus Dexamethasone
Number of Participants With Minimal Residual Disease (MRD) Negativity Rate221
PrimaryProgression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)

PFS is time from randomization until earliest date of progressive disease (PD), or death due to any cause per investigator-assessed response per IMWG. PD is ≥25% increase from nadir in any of following: serum M-protein (absolute increase ≥0.5 gram per deciliter \[g/dL\]),urine M-protein(absolute increase ≥200 mg/24hr),difference between involved/uninvolved FLC levels (absolute increase \>10 mg/dL) in patients without measurable serum and urine M-protein levels, or bone marrow plasma-cell percentage irrespective of baseline status (absolute increase ≥10%) in patients without measurable serum and urine M-protein levels and without measurable involved FLC levels; appearance of new lesion,≥50% increase in longest diameter of a lesion previously measured \>1cm in short axis, or ≥50% increase from nadir in sum of products of two longest perpendicular diameters of more than 1 lesion; ≥50% increase in circulating plasma cells (minimum of 200 cells/microliter) if this is only measure of disease.

Time frame:
Up to 27 months
Reported as:
Median · Months
Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)
MonthsBelantamab MafodotinPomalidomide Plus Dexamethasone
Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)11.2 (6.4 to 14.5)7.0 (4.6 to 10.6)
Statistical analysis
  • Belantamab Mafodotin vs Pomalidomide Plus Dexamethasone · Log Rank · p = 0.558 · Hazard ratio (hr): 1.03 · 95% CI 0.72 to 1.47One-sided p-value from stratified log-rank test were adjusted for previous treatment with anti-CD38,ISS staging and number of prior lines of therapy.

Adverse events

Collected over All-cause mortality, Non-Serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs) were collected up to approximately 263 weeks. The results presented are based on data cut-off date 22 April 2025.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belantamab Mafodotin139/217 (64.1%)101/217 (46.5%)205/217 (94.5%)
Pomalidomide Plus Dexamethasone71/102 (69.6%)45/102 (44.1%)93/102 (91.2%)
Most frequent serious events
Showing 10 of 120
Most frequent serious events
EventBelantamab MafodotinPomalidomide Plus Dexamethasone
PneumoniaInfections and infestations7/21710/102
COVID-19 pneumoniaInfections and infestations3/2175/102
Febrile neutropeniaBlood and lymphatic system disorders1/2175/102
ThrombocytopeniaBlood and lymphatic system disorders9/2171/102
COVID-19Infections and infestations5/2174/102
PyrexiaGeneral disorders8/2170/102
SepsisInfections and infestations2/2173/102
AnaemiaBlood and lymphatic system disorders6/2171/102
Respiratory tract infectionInfections and infestations1/2172/102
Urinary tract infectionInfections and infestations4/2170/102
Most frequent other events
Showing 10 of 53
Most frequent other events
EventBelantamab MafodotinPomalidomide Plus Dexamethasone
Vision blurredEye disorders105/2177/102
NeutropeniaBlood and lymphatic system disorders27/21741/102
Dry eyeEye disorders82/2173/102
Foreign body sensation in eyesEye disorders80/2175/102
ThrombocytopeniaBlood and lymphatic system disorders72/21735/102
AnaemiaBlood and lymphatic system disorders63/21735/102
Eye irritationEye disorders63/2173/102
PhotophobiaEye disorders63/2174/102
Eye painEye disorders49/2170/102
Visual acuity reducedEye disorders40/2171/102

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(YEARS)Belantamab MafodotinPomalidomide Plus DexamethasoneTotal
Mean66.3 ± 9.6766.6 ± 9.6866.4 ± 9.66
Sex: Female, Male
Sex: Female, Male(Participants)Belantamab MafodotinPomalidomide Plus DexamethasoneTotal
Female10041141
Male11866184
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belantamab MafodotinPomalidomide Plus DexamethasoneTotal
ASIAN471966
BLACK OR AFRICAN AMERICAN314
WHITE16284246
NOT REPORTED639
08

Study locations

136 sites
  • GSK Investigational Site
    Tucson, Arizona 85715, United States
  • GSK Investigational Site
    Pueblo, Colorado 81008, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Omaha, Nebraska 68130, United States
  • GSK Investigational Site
    Clifton Park, New York 12065, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45236, United States
  • GSK Investigational Site
    Corvallis, Oregon 97330, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Tyler, Texas 75702, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Gosford NSW, New South Wales 2250, Australia
  • GSK Investigational Site
    Liverpool, New South Wales 2170, Australia
  • GSK Investigational Site
    St Leonards, New South Wales 2065, Australia
  • GSK Investigational Site
    Woodville, South Australia 5011, Australia
  • GSK Investigational Site
    Hobart, Tasmania 7000, Australia
  • GSK Investigational Site
    Clayton, Victoria 3168, Australia
  • GSK Investigational Site
    Fitzroy, Victoria 3065, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    St Albans, 03021, Australia
  • GSK Investigational Site
    Bruges, 8000, Belgium
  • GSK Investigational Site
    Brussels, 1090, Belgium
  • GSK Investigational Site
    Brussels, 1200, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Kortrijk, 8500, Belgium
  • GSK Investigational Site
    Yvoir, 5530, Belgium
  • GSK Investigational Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • GSK Investigational Site
    Curitiba, 80530-010, Brazil
  • GSK Investigational Site
    Fortaleza, 60115-281, Brazil
  • GSK Investigational Site
    Porto Alegre, 90110-270, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 22793-080, Brazil
  • GSK Investigational Site
    São Paulo, 01321001, Brazil
  • GSK Investigational Site
    São Paulo, 01509-900, Brazil
  • GSK Investigational Site
    São Paulo, 04537-080, Brazil
  • GSK Investigational Site
    São Paulo, 05651-901, Brazil
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Plovdiv, 4000, Bulgaria
  • GSK Investigational Site
    Sofia, 01431, Bulgaria
  • GSK Investigational Site
    Sofia, 1000, Bulgaria
  • GSK Investigational Site
    Sofia, 1407, Bulgaria
  • GSK Investigational Site
    Sofia, 1606, Bulgaria
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Beijing, 100000, China
  • GSK Investigational Site
    Beijing, 100050, China
  • GSK Investigational Site
    Beijing, 100191, China
  • GSK Investigational Site
    Beijing, 100730, China
  • GSK Investigational Site
    Changsha, 130012, China
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Guangzhou, 510080, China
  • GSK Investigational Site
    Hangzhou, 310009, China
  • GSK Investigational Site
    Nanchang, 330006, China
  • GSK Investigational Site
    Shenzhen, 518029, China
  • GSK Investigational Site
    Tianjin, 300020, China
  • GSK Investigational Site
    Tianjin, 300060, China
  • GSK Investigational Site
    Xuzhou, 221006, China
  • GSK Investigational Site
    Zhengzhou, 450052, China
  • GSK Investigational Site
    Le Mans, 72015, France
  • GSK Investigational Site
    Montpellier, 34295, France
  • GSK Investigational Site
    Poitiers, 86021, France
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Tübingen, 72076, Germany
  • GSK Investigational Site
    Athens, 10676, Greece
  • GSK Investigational Site
    Athens, 115 28, Greece
  • GSK Investigational Site
    Haidari - Athens, 12462, Greece
  • GSK Investigational Site
    Larissa, 41 110, Greece
  • GSK Investigational Site
    Pátrai, 26500, Greece
  • GSK Investigational Site
    Thessaloniki, 54007, Greece
  • GSK Investigational Site
    Thessaloniki, 57010, Greece
  • GSK Investigational Site
    Budapest, 1083, Hungary
  • GSK Investigational Site
    Budapest, 1088, Hungary
  • GSK Investigational Site
    Budapest, 1097, Hungary
  • GSK Investigational Site
    Debrecen, 4012, Hungary
  • GSK Investigational Site
    Kaposvár, 7400, Hungary
  • GSK Investigational Site
    Nyíregyháza, 4400, Hungary
  • GSK Investigational Site
    Bologna, 40138, Italy
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Catanzaro, 88100, Italy
  • GSK Investigational Site
    Milan, 20122, Italy
  • GSK Investigational Site
    Milan, 20141, Italy
  • GSK Investigational Site
    Pavia, 27100, Italy
  • GSK Investigational Site
    Perugia, 05100, Italy
  • GSK Investigational Site
    Ravenna, 48123, Italy
  • GSK Investigational Site
    Roma, 00161, Italy
  • GSK Investigational Site
    San Giovanni Rotondo FG, 71013, Italy
  • GSK Investigational Site
    Siena, 53100, Italy
  • GSK Investigational Site
    Shibuya-Ku, Tokyo 150-8935, Japan
  • GSK Investigational Site
    Aichi, 467-8602, Japan
  • GSK Investigational Site
    Chiba, 277-8567, Japan
  • GSK Investigational Site
    Ehime, 790-8524, Japan
  • GSK Investigational Site
    Fukushima, 960-1295, Japan
  • GSK Investigational Site
    Gifu, 503-8502, Japan
  • GSK Investigational Site
    Gunma, 377-0280, Japan
  • GSK Investigational Site
    Hokkaido, 060-8648, Japan
  • GSK Investigational Site
    Kyoto, 602-8566, Japan
  • GSK Investigational Site
    Kyoto, 603-8151, Japan
  • GSK Investigational Site
    Osaka, 565-0871, Japan
  • GSK Investigational Site
    Tokyo, 108-8639, Japan
  • GSK Investigational Site
    Amersfoort, 3813 TZ, Netherlands
  • GSK Investigational Site
    Gdansk, 80-214, Poland
  • GSK Investigational Site
    Krakow, 30510, Poland

Showing the first 100 of 136 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0. PubMed 37793771 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Sep 2022, 29 months.

Results were first posted in Oct 2023, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 29 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2019
First posted
Nov 14, 2019
StartActual
Apr 2, 2020
Primary completionActual
Sep 12, 2022
CompletionEst.
Mar 11, 2027
Results first posted
Oct 6, 2023
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04162210
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 14, 2019
Start date
Apr 2, 2020
Primary completion
Sep 12, 2022
Completion
Mar 11, 2027 (estimated)
Results posted
Oct 6, 2023
Last update
Jul 1, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belantamab mafodotin

Start the discussion